

Multidrug-Resistant *Streptococcus pneumoniae* Infections

Current and Future Therapeutic Options

Françoise Van Bambeke,¹ René R. Reinert,² Peter C. Appelbaum,³ Paul M. Tulkens¹ and Willy E. Peetermans⁴

- 1 Unité de Pharmacologie Cellulaire et Moléculaire, Université Catholique de Louvain, Brussels, Belgium
- 2 Institute for Medical Microbiology, National Reference Center for Streptococci, University Hospital (RWTH), Aachen, Germany
- 3 Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania, USA
- 4 Department of Internal Medicine-Infectious Diseases, Katholieke Universiteit Leuven, University Hospital Gasthuisberg, Leuven, Belgium

Contents

Abstract	2355
1. Antibacterial Resistance in <i>Streptococcus pneumoniae</i>	2356
1.1 Main Mechanisms of Resistance	2356
1.2 Epidemiology of Resistance	2356
2. Current Therapeutic Options for Multidrug-Resistant (MDR) <i>S. pneumoniae</i>	2365
2.1 Clinical Implication of Antimicrobial Resistance	2365
2.1.1 Penicillin Resistance	2365
2.1.2 Macrolide Resistance	2365
2.1.3 Fluoroquinolone Resistance	2365
2.2 Combination Therapy	2372
2.3 Current Treatment of MDR <i>S. pneumoniae</i> Infections	2372
3. New Drugs in Development for <i>S. pneumoniae</i> Infections	2373
4. Conclusion	2375

Abstract

Antibacterial resistance in *Streptococcus pneumoniae* is increasing worldwide, affecting principally β -lactams and macrolides (prevalence ranging between \approx 1% and 90% depending on the geographical area). Fluoroquinolone resistance has also started to emerge in countries with high level of antibacterial resistance and consumption. Of more concern, 40% of pneumococci display multi-drug resistant phenotypes, again with highly variable prevalence among countries.

Infections caused by resistant pneumococci can still be treated using first-line antibacterials (β -lactams), provided the dosage is optimised to cover less susceptible strains. Macrolides can no longer be used as monotherapy, but are combined with β -lactams to cover intracellular bacteria. Ketolides could be an alternative, but toxicity issues have recently restricted the use of telithromycin in the US. The so-called respiratory fluoroquinolones offer the advantages of easy administration and a spectrum covering extracellular and intracellular pathogens. However, their broad spectrum raises questions regarding the global risk of resistance selection and their safety profile is far from optimal for wide use in the community. For multi-drug resistant pneumococci, ketolides and fluoroquinolones could be con-

sidered. A large number of drugs with activity against these multi-drug resistant strains (cephalosporins, carbapenems, glycopeptides, lipopeptides, ketolides, lincosamides, oxazolidinones, glycylcyclines, quinolones, deformylase inhibitors) are currently in development. Most of them are only new derivatives in existing classes, with improved intrinsic activity or lower susceptibility to resistance mechanisms. Except for the new fluoroquinolones, these agents are also primarily targeted towards methicillin-resistant *Staphylococcus aureus* infections; therefore, demonstration of their clinical efficacy in the management of pneumococcal infections is still awaited.

Streptococcus pneumoniae is a major cause of morbidity and mortality in humans, associated with respiratory tract infections (community-acquired pneumonia [CAP]), bacteraemia and meningitis.^[1,2] The treatment of these infections remains challenging because of the worldwide increase in antibacterial resistance,^[3] and of the emergence of multidrug-resistant (MDR) phenotypes.^[4]

Beginning with current epidemiological data on resistance, this review analyses the current therapeutic options for MDR pneumococci, and also briefly presents the molecules in development with improved activity against these bacteria.

1. Antibacterial Resistance in *Streptococcus pneumoniae*

1.1 Main Mechanisms of Resistance

Table I illustrates the most important mechanisms of resistance described so far in *S. pneumoniae*. β -Lactam resistance is mediated by stepwise alterations of penicillin-binding proteins (PBPs), resulting in decreased affinity of PBP1a, PBP2x and PBP2b. In resistant isolates, PBPs are encoded by mosaic genes that contain sequence blocks highly divergent from those of sensitive strains. They have been recognised as the product of transformation events, resulting from horizontal gene transfer not only among pneumococcal clones, but also among pneumococci and commensal viridans group streptococci.^[5] Macrolide resistance is usually caused by the presence of the *erm(B)* or the *mefE*, renamed *mef(A)*, resistance determinants. The *erm(B)* protein encodes a 23S ribosomal RNA methylase and most pneumococcal strains that harbour this gene are resistant to 14-, 15- and 16-membered-ring macrolides, lincosamides and streptogramin B (MLS_B phenotype).

The *mef(A)* protein encodes an efflux pump that leads to resistance to 14- and 15-membered-ring macrolides only.^[6,7] Other mechanisms of target modifications have been described in a few clinical pneumococcal isolates.^[8-11] Resistance to quinolones is usually due to mutations in topoisomerases (mainly in the *parC* or *gyrA* subunits).^[12] While single mutations already reduce the activity of weak molecules (ciprofloxacin, and to some extent, levofloxacin^[13]), multiple mutations in both targets are required to cause minimum inhibitory concentration (MIC) elevation for more potent molecules (moxifloxacin, gemifloxacin, garenoxacin).^[14] In addition, efflux mechanisms also affect the activity of ciprofloxacin and, to a lesser extent, levofloxacin.^[15,16]

1.2 Epidemiology of Resistance

Large-scale surveillance programmes have been designed in the last few decades to look for trends in antimicrobial resistance in *S. pneumoniae*. These programmes remain essential in the setting-up of evidence-based treatment guidelines. Table II summarises the current epidemiology of resistance to β -lactams, macrolides and fluoroquinolones worldwide. Breakpoint values for susceptibility or resistance are based on Clinical and Laboratory Standards Institute guidelines.^[21] Of note is that penicillin breakpoints have been recently raised for non-meningitis isolates to ≤ 2 mg/L (susceptible; S), 4 mg/L (intermediate; I) and ≥ 8 mg/L (resistant; R). This change will cause an artificial but drastic decrease in the percentage of so-called 'resistant' isolates and will classify as non-resistant strains with mutated PBPs. This highlights the risk of using S-I-R classification of strains rather than considering

Table I. Main mechanisms of antimicrobial resistance in *Streptococcus pneumoniae*

Antimicrobial class	Drugs affected	Genetic support	Mechanism of resistance	References
β-Lactams	All to a variable extent	Mosaic genes	Decreased affinity of PBP1a, PBP2x and PBP2b	17
MLS _B ; ketolides	All; multiple mutations needed to confer resistance to ketolides	<i>erm(B)</i>	Methylation of 23S rRNA	18
Macrolides	14- and 15-membered-ring	<i>mef(A)</i>	Active efflux	6,7
MLS _B	All	Point mutations	Mutation in the domain V of 23S rRNA critical for macrolide binding	8-11
MLS _B ; ketolides	All; multiple mutations needed to confer resistance to ketolides	Point mutations	Mutation in ribosomal proteins L4 and L22	8,10,11
Macrolides, lincosamides	14- and 15-membered-ring, inducibly resistant to lincosamides	<i>erm(A)</i>	Methylation of 23S rRNA	19
Fluoroquinolones	All to variable extent	Point mutations	Mutation in <i>parC</i> or/and <i>gyrA</i>	12
Fluoroquinolones	Norfloxacin, ciprofloxacin, levofloxacin	<i>pmrA</i> , <i>patA/patB</i>	Active efflux	15,16
Tetracyclines	All; glycyclcyclines not affected	<i>tet(A)</i> , <i>tet(O)</i>	Ribosomal protection	18
Oxazolidinones	Linezolid ^a	Point mutations	Mutation in domain V of 23S RNA	20
Trimethoprim		Point mutations	Mutation in the dihydrofolate reductase gene	18
Sulfonamides	All	Repetition of amino acids	Dihydropteroate synthase	18
Chloramphenicol		<i>cat</i>	Chloramphenicol acetyltransferase	18

a In pneumococci, resistance to linezolid has only been described *in vitro* so far. Other oxazolidinones have not yet been evaluated in this respect.

MLS_B = macrolides, lincosamides and streptogramin B; **PBP** = penicillin binding protein; **rRNA** = ribosomal RNA.

Table II. Worldwide prevalence of resistance to penicillin, macrolides and levofloxacin in *Streptococcus pneumoniae*

Country	Study design		Resistance (%)		Reference		
	study period	no. of isolates	age groups	specimen diagnosis	penicillin (I/R) ^a	macrolide ^b	levofloxacin ^c
Africa							
Kenya	1998–9	277	Adults	CAP	I+R: 43.3		24
Mozambique	2002–3	127	<15y	IPD	I: 14 R: 0	1	25
	2002–3	248	<15y	NPC	I: 52 R: 0	2	25
South Africa	2000–1	729	Children and adults	RTI	I: 30 R: 46	62	0
	2003	598	ND	CA-RTI	I: 22 R: 50.1	52.2	27
Latin America							
Argentina	1999–2000	55	ND	CA-RTI	I: 10.9 R: 16.4	10.9	0
	1999–2000	55	ND	CAP			3
	2000–2	134	Adults	CAP		15.6	
	1999–2003	291	ND	CA-RTI	I: 10.9→6.3 R: 16.4→13.4	10.9→18.1	
Brazil	1996–2000	420	Children and adults	IPD, n-IPD, LRTI	I: 18.1 R: 1.7 I+R : 20→19.5	3.1→5.2	
	1999–2000	260	ND	CA-RTI	I: 25.8 R: 8.1	6.9	1
	1999–2000	260	ND	CAP			0
	1999–2003	989	ND	CA-RTI	I: 25.8→20.3 R: 8.1→10.1	5.8→4.7	
Mexico	1999–2000	203	ND	CA-RTI	I: 32.5 R: 24.1	27.6	1.5
	1999–2000	203	ND	CAP			1
	1999–2003	557	ND	CA-RTI	I: 32.5→21.3 R: 24.1→23.8	26.6→27.5	
Peru	1997–2003	272	<2y	NPC	I: 10 R: 12.7 I+R: 5.3→20		
	2003	74	ND	CA-RTI	I: 5.3 R: 28.9	15.8	
North America							

Continued next page

Table II. Contd

Country	Study design		age groups	specimen diagnosis	Resistance (%)			Reference
	study period	no. of isolates			penicillin (I/R) ^a	macrolide ^b	levofloxacin ^c	
Canada	1997–2002	6 991	Children and adults	RTI	I: 14.6 R: 5.6	9.9	0.5→1.1	33
	1999–2003	2 132	ND	CA-RTI	I: 10.6 8.8 R: 10.6→8.3	15.7→14.7		27
	2002	2 539	Children and adults	all sites	I: 8.5 R: 6.5	14	2.7 ^c	34
USA	1999–2000	337	ND	CAP			3	29
	2000–3	31 001	Children and adults	CA-RTI	I: 12.5→15.3 R: 26.3→20.2	29.4 (31–29.2)	0.9	35
	1999–2003	1 145	ND	CA-RTI	I: 10.4→18.7 R: 32.6→28.7	30.6→35.4		27
	2002–3	1 817	ND	RTI, CSF, blood	I: 15.7 R: 18.5	29.5		36
	2003–4	1 479	ND	RTI	I: 18.7 R: 13.7	25.4	1.3	37
Asia–Far East								
China	1999–2000	70	ND	CAP			14.3	29
	1995–2001	265	Children and adults	IPD	48 in <13y 30.9 in adults	63	3.8	38
	1999–2003	260	ND	CA-RTI	I: 9.5→17.1 R: 0→4.9	50.8→68.3		27
Hong Kong	1999–2003	291	ND	CA-RTI	I: 1.4→8.6 R: 57.1→64.3	70→82.9		27
Japan	1994–2002	1 860	ND				I: 6.3→0.5 R: 2.8→2	39
	1999–2002	1 752	ND	RTI	I: 19.8→28 R: 44.5→35.9	77.9→79.9	1.2	40
	1999–2003	2 526	ND	CA-RTI	I: 19.8→26.9 R: 44.5→35	77.6→79.3		27
	2001–3	114	Adults	CAP	I: 57.9 R: 22.8	75.4		41
	2002–4	392	Children	CAP	I: 39.3 R: 52.3	79.1		42
Asian Russia	2001–2	912	<5y	NPC	I: 9 R: 0.6	3.7	0	43
Taiwan	2003	137	ND	CA-RTI	I: 8.8 R: 65.7	91.2		27

Continued next page

Table II. Contd

Country	Study design		age groups	specimen diagnosis	Resistance (%)			Reference
	study period	no. of isolates			penicillin (I/R) ^a	macrolide ^b	levofloxacin ^c	
	1999–2004	286	≤14y	IPD	I: 50.7 R: 25.5	93	0.3	44
Asia–Middle East								
Israel	1998–9	437	<13y	Blood and CSF	I: 22 R: 13	10		45
	2003	68	ND	CA-RTI	I: 10.3 R: 26.5	22.1		27
Saudi Arabia	2000	154	Children and adults	'Clinically significant'	I: 44.2 R: 14.9	15.6	1.3	46
	2003	76	ND	CA-RTI	I: 32.5 R: 35.5	23.7		27
Europe								
Austria	1999–2000	57	ND	CAP			0	29
	1996–2002	3 012	ND	ND	I: 2.9 R: 2.2	3.2		47
	2001–3	77	≤5y	IPD	I: 21.4 R: 0	33.9		48
Belgium	2001–3	160	Adults	'Clinically significant'	I+R: 4.4	10	0	49
	1999–2000	637	ND	IPD		36.6		50
	2001–3	148	Adults	'Clinically significant'	I+R: 11.5	23.7	0.7	49
	2003–4	815	Children and adults	N-IPD	I: 15→14.7 R: 8.4→6.4	25.3→24.5	I: 3.3→2.8 R: 1.5→0.2	51
Estonia	2000–3	49	Adults	LRTI	0	2.0		52
Finland	1999–2000	910	ND	IPD	I: 4.0 R: 1.5	6.9		53
	1997–2002	31 609	ND	ND	6.8→8.5	5.5→15		54
	2002	1 007	ND	IPD (129)/n-IPD (878)		21.5		55
France	2000–2	35	≤16y	IPD	I: 31.5 R: 14.3	48.6	0	56
	2000–2	222	Adults	IPD	I: 31.5 R: 16	56.8	0.4	56
	2001–3	443	Adults	'Clinically significant'	I+R: 47.6	46.1	0.9	49
Germany	1998–9	961	Children and adults	LRTI	I+R: 6.6	10.6	0.1	57
	1999–2000	325	ND	CAP			0.3	29
	2001–3	630	adults	'Clinically significant'	I+R: 6	10.6	0.4	49

Continued next page

Table II. Contd

Country	Study design		age groups	specimen diagnosis	Resistance (%)			Reference
	study period	no. of isolates			penicillin (I/R) ^a	macrolide ^b	levofloxacin ^c	
	1997–2004	1 643	children	IPD	I: 5.1 R: 1 I+R: 0.7→11.3	9.2→27.9		58
Greece	1999–2000	145	ND	'Clinical isolates'		42.8		59
Hungary	1999–2000	54	ND	CAP			0	29
	2000–2	304	ND	IPD/n-IPD	I: 37 R: 2 I+R: 35	41.7	0	60
Italy (North-East)	Since 1997	ND	ND	ND	I+R: 35	18		61
Italy	1999–2000	114	ND	CAP			0	29
	2001–2	ND	ND	Blood	I+R: 10.8	37.6		62
	2000–2	1 623	ND	ND	I+R: 15.2→16.1	37.9→43.7	0.2	63
	2001–3	462	Adults	'Clinically significant'	I+R: 13	35.5	1.3	49
	2001–4	551	ND	CAP			5.6	64
Norway	1993–2002	2 200	ND	IPD/n-IPD		33 (IPD) 27 (n-IPD)		65
Poland	1999–2000	68	ND	CAP			0	29
	1998–2002	887	Children and adults	IPD/n-IPD	I+R: 8.7→20.3	ND		66
	1999–2003	351	ND	CA-RTI	I: 13.2→6.9 R: 13.2→23.1	23.5→29.2		27
Portugal	1999–2000	108	ND	CAP			0	29
	1999–2001	1 210	76% adults 24% ≤18y	IPD/n-IPD	I: 15.5 R: 9	13.1		67
	2001–3	174	adults	'Clinically significant'	I+R: 19	10.3	1.2	49
	1994–2004	1 331	children and adults	IPD	I+R: 12→23.2	3.7→9.1	0.3	68
European Russia	2001–2	1 144	<5y	NPC	I: 13.7 R: 0.2	4.9	0	43
Slovenia	1999–2004	ND	ND	IPD/n-IPD		4.6→11.1 (IPD) 12.8→20.2 (n-IPD)		69
Spain	1999–2000	133	ND	CAP			0	29
	1999–2002	125	mean age: 59.6y	CAP	I+R: 34	33		70
	2001–2	2 721	ND	CAP	I: 23.9 R: 20.0	35.2		71

Continued next page

Table II. Contd

Country	Study design		age groups	specimen diagnosis	Resistance (%)			Reference
	study period	no. of isolates			penicillin (I/R) ^a	macrolide ^b	levofloxacin ^c	
Switzerland	2001–3	310	adults	'Clinically significant'	I+R: 61.9	43.6	1	49
	1999–2003	284	ND	CA-RTI	I: 8.1→2.9 R: 4.5→8.7	9→13		27
The Netherlands	2001–3	52	Adults	'Clinically significant'	I+R: 17.3	17.3	0	49
	1999–2000	51	ND	CAP			0	29
	2001–2	797	ND	IPD/n-IPD	I: 3.4 R: 0.9	7.4		72
	ND	264	ND	ND	I: 40.0 R: 7.6	15.9		73
	1994–2002	669	ND	'Clinical isolates'		13.6		74
Turkey	1999–2000	77	ND	CAP			0	29
	1999–2003	357	ND	CA-RTI	I: 20.7→17.4 R: 14.9→19.4	14.9→18.4		27
	2002–3	238	Children	NPC	I: 17.9 R: 7	13.7		75
UK	1999–2000	91	ND	CAP			0	29
	ND	831	Children	'Clinical isolates'	I: 3.7 R: 3.7	8.8		76
Oceania								
Australia	1999–2000	114	ND	CAP			0	29
	2002	183	ND		I: 14 R: 38	53		77

a MIC 0.12–1 mg/L for intermediate strains and ≥ 2 mg/L for resistant strains, according to the CLSI guidelines, which were valid until mid-2007.

b Intermediate and resistant strains were counted together; erythromycin MIC = 0.5 mg/L for intermediate strains and ≥ 1 mg/L for resistant strains, according to CLSI guidelines.

c Intermediate and resistant strains were counted together; levofloxacin MIC = 4 mg/L for intermediate strains and ≥ 8 mg/L for resistant strains, according to the CLSI guidelines.

CAP = community-acquired pneumonia; **CA-RTI** = community-acquired respiratory tract infection; **CLSI** = Clinical and Laboratory Standards Institute; **CSF** = cerebro-spinal fluid; **I** = intermediate level of resistance (MIC = 0.12–1 mg/L), according to the CLSI guidelines; **IPD** = invasive pneumococcal disease; **LRTI** = lower respiratory tract infections; **MIC** = minimum inhibitory concentration; **ND** = no data; **n-IPD** = non-invasive pneumococcal disease; **NPC** = nasopharyngeal carriage; **R** = high level of resistance (MIC ≥ 2 mg/L), according to the CLSI guidelines; **RTI** = respiratory tract infections; → indicates figures separated by an arrow show evolution over the study period.

actual MIC values. The European Committee on Antimicrobial Susceptibility Testing (EUCAST)^[22] breakpoints have not yet been published but the European agency will definitely propose lower values.

A low prevalence of penicillin resistance is observed in countries of Northern, Central and Western Europe, such as Germany and Austria. In contrast, high rates are observed in France, Spain, the US, Mexico, Africa and Asia, whereas moderate levels of resistance are reported from Belgium, Portugal, Switzerland, Italy, Canada, and most countries from Latin America. Macrolide resistance is almost parallel to that of β -lactams. Fluoroquinolone resistance begins to emerge in countries characterised by an important consumption of these drugs, together with high-resistance rates to other classes of antimicrobials, as is the case in the US, Mexico, Canada, France, Italy and Asian countries. However, the still low prevalence of fluoroquinolone resistance may be misleading since it probably hides a large reservoir of strains that have already acquired a first mutation, mostly in the DNA-gyrase system (surveillance studies generally use levofloxacin as an indicator of fluoroquinolone resistance, but first-step mutants would be more easily detected with ciprofloxacin^[23]).

This inter-country variability has been documented in numerous surveillance studies, such as the Pneumoworld study,^[49] the PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) study 1999–2000,^[78] the Alexander Project^[79,80] and the SENTRY Antimicrobial Surveillance Program.^[81,82] Also of interest is the trend to a decreased prevalence of resistance, mainly to β -lactams, in some parts of the world, such as the US and some European countries.

Of more concern, a number of studies have reported an increase over the last few years in the prevalence of MDR pneumococci in the US^[37,83,84] and in other parts of the world, particularly Asia,^[85–88] (the first mention of such strains apparently resistant to penicillin and other antibacterials appeared in the Time magazine in 1977^[89]). The

frequency of isolates that were resistant to two or more classes of antibacterials in 2002 has been analysed globally and for each country participating in the PROTEKT study (table III). Globally, more than one-third of the *S. pneumoniae* isolates were MDR. The highest prevalence of multidrug resistance was among the Far Eastern countries, followed by South Africa, France, Hungary, Spain and Mexico. The Netherlands, Russia, Sweden and the UK all had low rates of multidrug resistance (<15%). Isolates that were resistant to three classes of antibacterials were the most prevalent globally ($\geq 10\%$). Yet, the US had a high prevalence of isolates resistant to four classes of antibacterials. Isolates resistant to seven classes of antibacterials were present in low numbers in France, Spain and South Korea, but at worryingly high levels in Hong Kong.^[90]

Multidrug resistance is often spread through resistant genetic clones and a small number of clones dominate the antimicrobial-resistant pneumococcal population.^[91] The most notable was first identified in Spain in the early 1980s (Spain^{23F} clone). This clone has spread globally and has been identified in the US, Mexico, South America, other European countries, South Africa and Asia. As a result of the evolution of international clones, an understanding of resistance patterns is essential to the successful control of these bacteria. Multilocus sequence typing is increasingly being used to identify the predominant clones.^[92,93] This method is highly portable, because any laboratory can compare the sequences of the seven loci in their isolates with those in a central database on the World Wide Web (<http://www.mlst.net>) and obtain the allelic profile of each isolate. Standardisation of the typing of strains using this technique, as well as pulsed-field gel electrophoresis and PBP fingerprinting, allowed the establishment in 1997 of the Pneumococcal Molecular Epidemiology Network, with the aim of global surveillance of antibiotic-resistant strains and of standardisation of nomenclature and classification of resistant clones.¹ Another strategy to avoid the spreading of MDR clones, while at the same time reducing the burden of pneumococcal disease,

1 The website of this network (<http://www.sph.emory.edu/PMEN/index.html>) presents the criteria for inclusion of clones in the database and depicts the main characteristics of the 43 epidemic clones described so far.

Table III. Frequency of multidrug resistance^a among isolates of *Streptococcus pneumoniae* by country in 2002 (reproduced from Reinert,^[90] with permission)

Country	No. of isolates	% of total isolates						
		2-MDR	3-MDR	4-MDR	5-MDR	6-MDR	7-MDR	total MDR
Latin America								
Argentina	80	7.5	8.8	1.3	3.8	0.0	0.0	21.3
Brazil	238	5.9	12.6	3.4	0.8	1.3	0.0	23.9
Ecuador	50	6.0	18.0	8.0	4.0	4.0	0.0	40.0
Mexico	194	13.4	29.4	10.3	3.1	6.2	0.0	62.4
Peru	74	4.1	18.9	13.5	8.1	1.4	0.0	45.9
North America								
Canada	628	2.7	7.2	1.4	3.0	1.9	0.0	16.2
USA	292	3.4	6.8	13.4	4.5	6.5	0.0	34.6
Asia								
China	74	5.4	13.5	56.8	5.4	16.2	0.0	97.3
Hong Kong	74	1.4	10.8	8.1	32.4	18.9	5.4	77.0
Japan	817	10.4	38.8	26.7	13.0	4.3	0.0	93.1
South Korea	123	4.9	15.4	4.1	12.2	46.3	0.8	83.7
Taiwan	137	1.5	27.7	8.0	31.4	24.1	0.0	92.7
Europe								
Austria	163	3.7	5.5	1.2	0.0	0.0	0.0	10.4
Belgium	137	7.3	23.4	4.4	3.6	2.2	0.0	40.9
Eire	117	2.6	12.8	6.0	4.3	0.9	0.0	26.5
France	216	6.9	17.1	6.5	20.8	19.4	0.9	71.8
Germany	623	2.6	9.3	1.6	0.2	0.2	0.0	13.8
Hungary	71	2.8	7.0	18.3	8.5	9.9	0.0	46.5
Italy	267	2.6	27.7	6.7	1.5	1.1	0.0	39.7
The Netherlands	59	1.7	8.5	0.0	0.0	0.0	0.0	10.2
Poland	76	5.3	13.2	5.3	2.6	3.9	0.0	30.3
Portugal	85	2.4	12.9	1.2	2.4	3.5	0.0	22.4
Russia	87	0.0	2.3	0.0	0.0	2.3	0.0	4.6
Spain	524	5.7	26.9	11.3	3.8	10.3	0.6	58.6
Sweden	75	0.0	4.0	5.3	0.0	0.0	0.0	9.3
Switzerland	104	1.9	13.5	1.9	1.9	2.9	0.0	22.1
Turkey	71	8.5	23.9	2.8	4.2	8.5	0.0	47.9
UK	104	0.0	2.9	0.0	0.0	1.0	0.0	3.8
Oceania								
Australia	128	1.6	8.6	1.6	0.8	5.5	0.0	18.0
Indonesia	0	NA	NA	NA	NA	NA	NA	NA
Global ^b								
	6320	4.8	13.6	9.2	6.3	7.7	0.2	41.8

a Drugs under study are benzylpenicillin (penicillin G), cefuroxime, erythromycin, clindamycin, telithromycin, quinupristin/dalfopristin, levofloxacin, tetracycline and co-trimoxazole (trimethoprim/sulfamethizole).

b Global figures for the whole collection; the table illustrates data for selected countries.

MDR = multidrug resistant; **NA** = not available.

is vaccination. The rate of antimicrobial-resistant invasive pneumococcal infections was indeed decreased in young children and older individuals after the introduction of the 7-valent paediatric conjugate vaccine in the US. However, as suspected at the time

of starting vaccination campaigns,^[94] this was accompanied by an increase in invasive disease caused by serotypes not included in the vaccine, some of them also being MDR.^[95-97] Currently, health authorities in many European countries have intro-

duced this vaccine into their childhood immunisation programmes, but data documenting the consecutive evolution in resistance rates in Europe are not yet available.

2. Current Therapeutic Options for Multidrug-Resistant (MDR) *S. pneumoniae*

2.1 Clinical Implication of Antimicrobial Resistance

The impact of antimicrobial resistance on clinical outcome in patients with pneumococcal pneumonia or invasive pneumococcal disease remains a controversial issue. The guidelines recently released by the European Respiratory Society^[98] and the Infectious Diseases Society of America/American Thoracic Society^[99] consensus guidelines on the management of CAP have, nevertheless, both taken antimicrobial resistance issues into consideration.

2.1.1 Penicillin Resistance

For pneumonia, only one report documents treatment failure of parenteral β -lactams in patients infected by resistant pneumococci,^[100] but the number of patients included, and in particular the microbiologically-assessable subgroup, was quite small. A meta-analysis also concluded that penicillin non-susceptibility was associated with a higher short-term mortality rate in hospitalised patients with pneumococcal disease, after adjustment for age, comorbidities and severity of illness.^[101] However, inadequate antimicrobial therapy did not appear to have contributed to the higher mortality in the penicillin non-susceptible group, so that the authors concluded that penicillin non-susceptibility must rather be considered as a prognostic factor, and that other factors may have a stronger influence on the outcome.^[102-104] Two reports also concluded that an initial discordant monotherapy with β -lactams was not associated with an increased mortality or clinical or bacteriological failures.^[105,106]

These observations have led to the conclusion that current antibacterial regimens are still effective in the treatment of penicillin-non-susceptible pneumococcal pneumonia with or without bacteraemia. Pharmacokinetic/pharmacodynamic (PK/PD) considerations may provide an explanation for these

findings. Serum antibacterial concentrations of adequately administered β -lactams do indeed exceed the MIC values of all penicillin non-susceptible and most penicillin-resistant pneumococci for at least 40–60% of the administration interval (see table IV for MIC distribution, and table V for pharmacokinetic and pharmacodynamic parameters). Only pneumococci with a penicillin MIC >4 mg/L may become problematic from a PK/PD point of view.^[107-109]

For meningitis, penicillin non-susceptibility has been associated with poor outcome in some patients but not in others,^[166-168] and it proved to be an independent determinant of mortality.^[169] PK/PD target attainment in the infected compartment is again probably critical, but difficult to evaluate, because the penetration of the antibacterial in the cerebrospinal fluid is influenced by the inflammation status and the addition of corticosteroids.^[170]

Current guidelines on empirical treatment of bacterial meningitis, therefore, recommend the addition of vancomycin to a third-generation cephalosporin in regions with emergent penicillin or cefotaxime non-susceptible pneumococci.^[171]

2.1.2 Macrolide Resistance

Several observational studies reported breakthrough bacteraemia and failure of macrolide treatment in patients with erythromycin-resistant pneumococcal bacteraemia.^[172-174] The increased risk of macrolide failure occurred irrespective of the underlying resistance mechanism as soon as the erythromycin MIC is >1 mg/L. However, other authors^[175] questioned the clinical relevance of *in vitro* macrolide resistance, in particular for low-level resistance due to the efflux.

On the basis of accumulating reports of failure with macrolides-azalides in the treatment of pneumococcal pneumonia due to resistant strains,^[109,176] the updated European and American guidelines recommend not to use macrolides as monotherapy anymore for the empirical treatment of CAP, especially in areas with high-resistance rates.^[98,99]

2.1.3 Fluoroquinolone Resistance

Several well documented reports of treatment failure with fluoroquinolones (ciprofloxacin, levofloxacin) in patients with fluoroquinolone-resistant pneumococcal disease have gained the attention of

Table IV. *In vitro* activity of reference drugs and molecules in development showing activity on *Streptococcus pneumoniae* (for the chemical structures of these compounds, please see the supplementary material [ArticlePlus] at <http://drugs.adisonline.com>)

Drug	Stage of development	Current target indications ^a	Resistance phenotype	MIC ₅₀ (mg/L)	MIC ₉₀ (mg/L)	Range (mg/L)	Reference
β-Lactams							
penicillin	Reference drug		PenS	0.016	0.03	0.016–0.06	110
			PenI	0.25	1	0.12–1	110
			PenR	2	4	2– >16	110
amoxicillin	Reference drug		PenS	≤0.016	0.03	≤0.016–0.12	110
			PenI	0.25	2	0.016–4	110
			PenR	2	8	0.03–16	110
cefuroxime	Reference drug		PenS	0.03	0.12	0.016–0.25	110
			PenI	0.5	4	0.03–4	110
			PenR	4	16	1– >64	110
ceftriaxone	Reference drug		PenS	0.016	0.03	0.016–0.12	110
			PenI	0.25	1	0.016–1	110
			PenR	1	2	0.12–32	110
cefotaxime	Reference drug		PenS	0.016	0.03	0.016–0.12	110
			PenI	0.25	1	0.016–1	110
			PenR	1	2	0.12–32	110
cefditoren	Approved	SSTI, pharyngitis, AECB, CAP	PenS	≤0.03	≤0.03	≤0.03–0.06	111
			PenI	0.25	0.5	≤0.03–1	111
			PenR	0.5	0.5	0.12–2	111
ceftobiprole	Phase III	SSTI, VAP, CAP	PenS	≤0.015	≤0.015	0.008–0.03	112
			PenI	0.06	0.12	≤0.008–1	112
			PenR	0.25	1	0.015–4	112
cefmatilen (S-1090)	Phase III ^b			0.063	1	0.004–1	113
ceftaroline TAK-599 (PPI-0903)	Phase II	SSTI, CAP	PenS	≤0.016	≤0.016	≤0.016–0.06	114
			PenI	0.03	0.06	0.016–0.12	114
			PenR	0.12	0.25	0.06–0.5	114
RWJ-54428 (MC-02479)	Phase II ^c		PenS	≤0.015	≤0.015	≤0.008–0.06	112
			PenI	0.125	0.25	0.015–0.25	112
			PenR	0.5	1	0.125–1	112
faropenem	Phase III	Sinusitis, AECB, CAP, SSTI	PenS	0.008	0.25	≤0.004–2	112
			PenI	≤0.004	0.008	≤0.004–0.12	112

Continued next page

Table IV. Contd

Drug	Stage of development	Current target indications ^a	Resistance phenotype	MIC ₅₀ (mg/L)	MIC ₉₀ (mg/L)	Range (mg/L)	Reference
			PenR	0.5	1	≤0.004–2	112
tomopenem (CS-023; RO4908463)	Phase II	Nosocomial pneumonia	PenS	≤0.03	≤0.03	≤0.03	115
			PenI	0.06	0.12	0.03–0.25	115
			PenR	0.12	0.25	0.06–0.5	115
			Glycolipopeptides				
vancomycin	Reference drug		PenS	0.5	0.5	0.1–0.5	116
			PenR	0.25		0.25–2	116
oritavancin	Phase III	SSTI, bloodstream	PenS	≤0.002	0.008	≤0.002–0.06	116
			PenR	≤0.002		≤0.002–0.06	116
telavancin	Phase III (HAP)	SSTI, <i>HAP</i>	PenS	0.016	0.016	0.008–0.03	117
			PenR				
dalbavancin	Phase III	SSTI, bloodstream	PenS	0.03	0.06	0.016–0.13	116
			PenR	0.03		0.008–0.13	116
daptomycin	Approved	SSTI	PenR		≤0.125	≤0.125	118
MX-2401	Preclinical	<i>Gram-positive infections</i>				0.125–2	119
Macrolides							
clarithromycin	Reference drug		ML-S	0.03	0.06	≤0.016–0.5	110
			ML-R	>16	>16	0.25–64	110
azithromycin	Reference drug		ML-S		0.125	0.125–2	120
			ML-R		128	2–128	120
Ketolides							
telithromycin	Approved	<i>CAP (AECB, and sinusitis; withdrawn for these indications in the US^[122]).</i>	ML-S	0.004	0.008	≤0.015	121
			ML-R	0.015	0.12	≤0.002–0.5	121
cethromycin	Phase III	<i>CAP, bronchitis, pharyngitis and sinusitis</i>	ML-S	0.001	0.002	≤0.004	121
			ML-R	0.004	0.015	≤0.002–1	121
EDP-420	Phase II	<i>CAP</i>	ML-S	0.03	0.03	≤0.015–0.5	123
			ML-R	0.06	0.5	≤0.015–2	123
FMA1485	preclinical	<i>RTIs</i>	ML-S		0.03		124
			ML-R		0.06		124
Lincosamides							
clindamycin	Reference drug			≤0.25	≤0.25	≤0.25	125

Continued next page

Table IV. Contd

Drug	Stage of development	Current target indications ^a	Resistance phenotype	MIC ₅₀ (mg/L)	MIC ₉₀ (mg/L)	Range (mg/L)	Reference
VIC105555	Preclinical			0.03	0.03	≤0.016–0.03	125
Streptogramins							
quinupristin/ dalfopristin	Approved	SSTI	ML-S	0.25	0.5	0.25–0.5	126
			ML-R	0.5	1	0.125–2	126
Oxazolidinones							
linezolid	Reference drug	SSTI, HAP, CAP	PenR	1	2	0.5–4	127
ranbezolid	Phase I, dropped off?	Nosocomial infections	PenR	0.5	1	0.06–2	127
Tetracyclines							
tetracycline	Reference drug		Tet-S	0.5		0.25–2	112
			Tet-R	64		8–128	112
doxycycline	Reference drug			0.25	0.5	≤0.25–32	33
Glycylcyclines							
tigecycline	Approved	SSTI, IAI, off-label: <i>pneumonia</i> caused by MDR organisms	Tet-S	0.25		0.12–0.5	112
			Tet-R	0.12		0.06–0.5	112
MK-2764	Phase I/(II)	Community-acquired and complicated infections of the skin and <i>pneumonia</i>	Tet-S	0.06	0.12	0.016–0.25	128
			Tet-R			≤0.06	129
Quinolones							
levofloxacin	Reference drug	RTIs, SSTI, UTIs	Q-S	1	1	0.25–2	112
			Q-R	8	16	1–32	112
moxifloxacin	Reference drug	CAP, AECB, sinusitis	Q-S	0.12	0.25	0.03–0.25	130
			Q-R	2	4	2–4	130
gemifloxacin	Reference drug	CAP, AECB	Q-S	0.03	0.03	0.008–0.06	130
			Q-R	0.25	0.25	0.12–4	130
garenoxacin	Phase III completed	RTIs, pelvic inflammation	Q-S	0.03	0.03	≤0.016–0.06	131
			Q-R	0.25	1	0.03–1	131
sitafoxacin	Phase III phototoxicity		Q-S	0.06	0.12	≤0.008–0.5	112
			Q-R			0.25–1	112
WCK-771A	Phase II	MRSA	All isolates	0.25	0.5	0.06–1	132
			Q-R	4	16	0.25–16	132
WCK-1152	Phase I	RTIs	All isolates	0.03	0.06	0.016–0.125	132

Continued next page

Table IV. Contd

Drug	Stage of development	Current target indications ^a	Resistance phenotype	MIC ₅₀ (mg/L)	MIC ₉₀ (mg/L)	Range (mg/L)	Reference
			Q-R	0.25	1	0.06–1	132
WCK-1153	Preclinical		All isolates	0.016	0.03	0.016–0.06	132
			Q-R	0.125	0.5	0.016–0.5	132
DX-619	Phase I		All isolates	0.007	0.03	0.002–0.6	133
			Q-R	0.03	0.25	0.015–0.5	134
DK-507K	Phase I		Q-S	0.06	0.125	0.03–0.25	135
	(discontinued for mild toxicity)		Q-R	0.25	0.5	0.25–1	135
DC-159a	Preclinical	<i>RTIs</i>	All isolates	0.12	0.12		136
			Q-R	1	2		136
DW-224a	Preclinical		Q-S	0.016	0.03	0.004–0.03	130
			Q-R	0.12	0.25	0.06–1	130
PGE 9262932	Preclinical		Q-S	≤0.015	≤0.015	≤0.015–0.5	137
			Q-R	0.06	0.12	≤0.015–0.5	137
olamufloxacin (HSR-903)				0.06	0.12	≤0.03–0.12	138
Diaminopyridine							
trimethoprim	Reference drug				>128		139
iclaprim	Phase III	SSTI			4		139
AR-709	Preclinical	<i>Upper and lower RTIs</i>	MDR	0.25	0.5	≤0.03–1	140
Deformylase inhibitors							
LBM415	Phase I	<i>RTIs</i>	PenR	0.5	1	0.06–4	141
			ML-R	0.5	4	0.016–16	141

a Indications where *S. pneumoniae* can be a causative agent are highlighted in italic characters.

b Last publication on this drug: 2002.

c Last publication on this drug: 2003.

AECEB = acute exacerbation of chronic bronchitis; **CAP** = community-acquired pneumonia; **HAP** = hospital-acquired (nosocomial) pneumonia; **IAI** = intra-abdominal infection; **MIC₅₀/MIC₉₀** = minimum concentration to inhibit growth of 50%/90% of isolates; **MDR** = multidrug resistant; **ML-R** = macrolide-lincosamide resistant; **ML-S** = macrolide-lincosamide sensitive; **MRSA** = methicillin-resistant *Staphylococcus aureus*; **PenI** = penicillin intermediate; **PenR** = penicillin resistant; **PenS** = penicillin sensitive; **Q-R** = quinolone resistant; **Q-S** = quinolone sensitive; **RTIs** = respiratory tract infections; **SSTI** = skin and soft tissue infection; **Tet-R** = tetracycline resistant; **Tet-S** = tetracycline sensitive; **VAP** = ventilator-associated pneumonia.

Table V. Pharmacokinetics and pharmacokinetic/pharmacodynamic (PK/PD) parameters of current drugs and molecules in clinical stage of development for *Streptococcus pneumoniae* infections

Drug	Proposed dosage	C _{max} (mg/L)	t _{1/2} (h)	AUC (mg • h/L)	Protein binding (%)	PK/PD parameter ^a	PK/PD break-point	Adequateness of PK/PD breakpoint with current MIC distributions	References
β-Lactams									
amoxicillin	500mg tid PO	5–11	1	13	17	fT >MIC ^b = 50% fT >MIC = 100%	2 0.2	= MIC ₅₀ PenR = MIC ₅₀ PenI	142,143
	1000mg tid IV	100	1	120	17	fT >MIC = 50% fT >MIC = 100%	2 0.2	= MIC ₅₀ PenR = MIC ₅₀ PenI	143,144
	1000mg qid IV	100	1	160	17	fT >MIC = 50% fT >MIC = 100%	4 0.6	>MIC ₅₀ PenR >MIC ₅₀ PenI	143,144
cefuroxime axetil	500mg bid PO	8	1.2	23	33	fT >MIC = 50% fT >MIC = 100%	0.5 0.01	= MIC ₅₀ PenI <MIC ₅₀ PenS	145
ceftriaxone	1g od IV	130	6	1006	90–95	fT >MIC = 50% fT >MIC = 100%	2 1	= MIC ₉₀ PenR = MIC ₅₀ PenR	143,146
	2g od IV	257	6	1703	90–95	fT >MIC = 50% fT >MIC = 100%	5 2	>MIC ₉₀ PenR = MIC ₉₀ PenR	143,146
cefotaxime	1g tid IV	102	1	200	30–50	fT >MIC = 50% fT >MIC = 100%	2 0.25	= MIC ₉₀ PenR = MIC ₅₀ PenI	143,147
	2g tid IV	214	1	400	30–50	fT >MIC = 50% fT >MIC = 100%	4 0.5	>MIC ₉₀ PenR = MIC ₅₀ PenI	143,147
cefditoren	400mg bid PO	4–5	1.3	14	88	fT >MIC = 50% fT >MIC = 100%	0.02 0.001	= MIC ₉₀ PenS <MIC ₅₀ PenS	143,148
ceftobiprole	500mg bid IV	35.5	3.4	150	48	fT >MIC = 50% fT >MIC = 100%	5 1	>MIC ₉₀ PenR = MIC ₉₀ PenR	143,149
ceftaroline	600mg bid IV	19	1.6	56	<20	fT >MIC = 50% fT >MIC = 100%	1 0.1	>MIC ₉₀ PenR >MIC ₉₀ PenI	143,150,151
faropenem	300mg bid PO	13.8	1.31	50	90	fT >MIC = 20% fT >MIC = 100%	0.2 0.03	>MIC ₉₀ PenI >MIC ₉₀ PenI	112,152
Glycolipopeptides									
vancomycin	15 mg/kg bid IV	20–50	4–8	260	10–55	fAUC/MIC >400	0.3	>MIC ₅₀	143,153
telavancin	7.5–10 mg/kg od IV	88	7–9	762	93	fAUC/MIC >10–20	4–2	>MIC ₉₀	154,155
Macrolides									
clarithromycin	500mg bid PO	2.1	4.3	14	70	fAUC/MIC >25	0.2	>MIC ₉₀ ML-S	143,156
azithromycin	500mg od PO	0.4	40–68	3.4	7–50	fAUC/MIC >25	0.1	= MIC ₉₀ ML-S	143,157,158
Ketolides									
telithromycin	800mg od PO	1.2	13	6	89	fAUC/MIC >25	0.02	>MIC ₉₀ ML-S = MIC ₅₀ ML-R	143,159,160

Continued next page

Table V. Contd

Drug	Proposed dosage	C _{max} (mg/L)	t _{1/2} (h)	AUC (mg • h/L)	Protein binding (%)	PK/PD parameter ^a	PK/PD break-point	Adequateness of PK/PD breakpoint with current MIC distributions	References
cethromycin	150mg od PO	0.18	4.9	0.9	86–96	fAUC/MIC >25	0.003	= MIC ₉₀ ML-S = MIC ₅₀ ML-R	143,161
Oxazolidinones									
linezolid	600mg bid PO	13	3.5	180	31	fAUC/MIC >50	4	>MIC ₉₀	162,163
Tetracyclines									
doxycycline	100mg od PO	1.7	14	40	82–93	fAUC/MIC >25	0.2	<MIC ₅₀	143,164
	200mg od PO	5.2	13	90	82–93	fAUC/MIC >25	0.5	= MIC ₉₀	143,164
Glycylcyclines									
tigecycline	50mg bid IV	0.5–0.6	37	5	79	AUC/MIC >12	0.5	>MIC ₅₀ Tet-R	164
Fluoroquinolones									
levofloxacin	500mg od PO	5	7	48	31	fC _{max} /MIC >8 fAUC /MIC >25 fAUC/MIC >125	0.4 1.5 0.3	<MIC ₅₀ Q-S >MIC ₉₀ Q-S <MIC ₅₀ Q-S	143,165
	750mg od PO	7	7	82	31	fC _{max} /MIC >8 fAUC /MIC >25 fAUC/MIC >125	0.6 2 0.4	<MIC ₅₀ Q-S >MIC ₉₀ Q-S <MIC ₅₀ Q-S	143,165
	500mg bid PO	5	7	96	31	fC _{max} /MIC >8 fAUC /MIC >25 fAUC/MIC >125	0.4 3 0.5	<MIC ₉₀ Q-S >MIC ₉₀ Q-S <MIC ₅₀ Q-S	143,165
moxifloxacin	400mg od PO	3.4	12	34	47	fC _{max} /MIC >8 fAUC /MIC >25 fAUC/MIC >125	0.2 0.5 0.2	= MIC ₉₀ Q-S >MIC ₅₀ Q-R >MIC ₉₀ Q-S	143,165
gemifloxacin	320mg od PO	1.2	8	10	60	fC _{max} /MIC >8 fAUC /MIC >25 fAUC/MIC >125	0.05 0.1 0.02	>MIC ₉₀ Q-S >MIC ₉₀ Q-S = MIC ₉₀ Q-S	143,165
garenoxacin	400mg od PO	5	14.2	60	75	fC _{max} /MIC >8 fAUC /MIC >25 fAUC/MIC >125	0.15 0.5 0.12	>MIC ₉₀ Q-S >MIC ₅₀ Q-R >MIC ₉₀ Q-S	143,165

a Breakpoint determined based on parameters predictive of antibacterial efficacy, as listed in the column. In some cases, two or three values are proposed, which correspond to the parameter for efficacy in immunocompetent patients and in immunocompromised patients or severe infections, respectively.

b Percentage of dosing interval that free drug concentrations remain above MIC.

AUC = area under the plasma/serum concentration-time curve; **bid** = twice daily; **C_{max}** = maximum plasma/serum concentration; **f** = free fraction of drug; **IV** = intravenous; **MIC** = minimum inhibitory concentration; **ML-R** = macrolide-lincosamide resistant; **ML-S** = macrolide-lincosamide sensitive; **od** = once daily; **PenI** = penicillin intermediate; **PenR** = penicillin resistant; **PenS** = penicillin sensitive; **PO** = orally; **qid** = four times daily; **Q-R** = quinolone resistant; **Q-S** = quinolone sensitive; **T** = time; **Tet-R** = tetracycline resistant; **tid** = three times daily; **t_{1/2}** = half-life.

Table VI. Risks factors for multidrug-resistant (MDR) *Streptococcus pneumoniae* infection and strategies for limiting their impact^[99,188-190]

Factors associated with carriage or infection by MDR <i>S. pneumoniae</i>		Strategies to implement
Host factors	Age (<2–5 and >65y)	Vaccination
	Co-morbidities	Global assessment of the patient
	Immunosuppression	
Environment factors	Geographic area with high-antibacterial consumption	Politics of restricted antibiotic use; promotion of guidelines
	High-population density, life in collectivity (daycare centres for children)	Hygiene
Drug-related factors	Administration of antibacterials in the previous weeks/months	Diagnostic methods for identification of bacterial infections
	Inappropriate antibacterial treatment in terms of:	a) use of local resistance data; avoiding the use of macrolides; critical appraisal of the interest of new drugs.
	a) antibacterial choice (risk for MDR: macrolides >cephalosporins >penicillins)	b) treatment duration as short as possible (5 days)
	b) treatment duration	c) optimisation of antibacterial dosages based on pharmacodynamic criteria; selection of antibacterials with higher PK/PD index within a class
	c) antibacterial dosage	

PK/PD = pharmacokinetic/pharmacodynamic.

the medical community.^[176,177] The level of *in vitro* fluoroquinolone resistance in pneumococci is still low (table II); however, physicians have to be vigilant for clinical failure especially in patients with comorbid illnesses, such as chronic obstructive pulmonary disease and a history of recent fluoroquinolone use.

The European and American guidelines advocate considering respiratory fluoroquinolones only as first-line agents in regions with clinically relevant resistance rates against the first-choice agents or in patients with major intolerance or allergy to the preferred antibacterials. Potent molecules with MIC values several dilutions below the breakpoint (see table V for pharmacodynamic breakpoints), should be preferred to minimise the risk of selecting first-step mutants.^[14] Misuse of respiratory fluoroquinolones as a result of incorrect indication, dose and duration must be avoided since it may drive the emergence of higher level resistance.^[98,99]

2.2 Combination Therapy

The use of combination therapy for severe (often bacteraemic) pneumococcal pneumonia remains controversial. Evidence in favour of β -lactam plus macrolide combination therapy comes from retrospective observational studies with an inherent risk of bias,^[178-180] and is therefore controversial.^[181,182] No benefit in survival or clinical efficacy of combining a β -lactam with an antibacterial active against

atypical pathogens in non-severe CAP was reported in a meta-analysis^[183] or Cochrane analysis.^[184] Prospective cohort studies could also not provide a clear answer.^[185-187] The discussion is still more complex when considering the option of fluoroquinolone monotherapy instead of a β -lactam plus macrolide.

However, it is noteworthy that all these studies were focused on the importance of broadening the spectrum to atypical pathogens, and not on the interest of combining drugs in empirical treatment for covering resistant strains.

2.3 Current Treatment of MDR *S. pneumoniae* Infections

Table VI lists the main determinants associated with MDR *S. pneumoniae* carriage or infection and the strategies that need to be implemented to avoid their spread.^[99,188-191] Among the most important factors, the recent use of antibacterials not only increases the risk of individual carriage and, therefore, of transmission, but also of developing invasive illness. This is probably as a result of the unmasking of minority MDR subpopulation upon antibacterial exposure.^[192] Key strategies for limiting further spread of MDR clones are through politics aimed at restricting the global consumption of antibacterials and at promoting their rational use. This implies the selection of more potent molecules within a drug family and the administration of appropriate dosages based on pharmacodynamics.

Table VII. Current therapeutic recommendations for community-acquired pneumonia (CAP) caused by multidrug-resistant (MDR) or non-MDR *Streptococcus pneumoniae* (based on;^[98,99] see for appropriate dosages)

Type of infection	European guidelines	American guidelines
CAP, outpatient	Amoxicillin or tetracycline Alternatives: amoxicillin/clavulanic acid, macrolide, respiratory fluoroquinolone	No risk factor for MDR: macrolide or doxycycline Risk factor for MDR or >25% ML resistance: respiratory fluoroquinolone; amoxicillin + macrolide; amoxicillin/clavulanic acid Alternatives to amoxicillin: ceftriaxone; cefuroxime Alternative to macrolide: doxycycline
CAP, inpatient	Penicillin ± macrolide Alternatives to penicillin: amoxicillin; amoxicillin/clavulanic acid; ceftriaxone; cefuroxime; ertapenem (in case of risk of co-infection by Gram-negative pathogens other than <i>Pseudomonas aeruginosa</i>) Alternative: respiratory fluoroquinolone PenI: high doses of amoxicillin; ceftriaxone; cefotaxime; respiratory fluoroquinolone; telithromycin PenR: respiratory fluoroquinolone; glycopeptide; linezolid	Respiratory fluoroquinolone, cefotaxime, ceftriaxone, ampicillin + macrolide Alternative to macrolide: doxycycline

ML = macrolide-lincosamide; **PenI** = penicillin intermediate; **PenR** = penicillin-resistant.

Therefore, current therapeutic options for antibacterial-resistant pneumococcal disease still rely upon adequately administered penicillins, aminopenicillins or third-generation cephalosporins (table VII).^[190,191] The exception is meningitis, where a combination of a third-generation cephalosporin and vancomycin is recommended in regions with emergent penicillin or cephalosporin non-susceptible pneumococcal strains (table VIII). Monotherapy with macrolides can no longer be recommended because of increasing resistance rates associated with clinical failure. A β -lactam plus macrolide combination is preferred by most authors for severe bacteraemic pneumococcal pneumonia, but it is still matter of debate for moderate pneumonia. Respiratory fluoroquinolones offer a valid alternative for respiratory pneumococcal infection with or without bacteraemia. Additional studies are needed to explore whether monotherapy with a respiratory fluoroquinolone is as good as a combination therapy of β -lactam plus coverage for atypical pathogens in severe CAP.

For MDR pneumococcal infections, respiratory fluoroquinolones and ketolides appear as useful alternatives,^[191] mainly based on their *in vitro* activity against penicillin-resistant, macrolide-resistant or MDR pneumococci (table IV), and on clinical trials in which resistant organisms were specifically examined.^[6,165,193] However, it must be noted that the use of telithromycin, the first marketed ketolide, is now restricted in the US the single indication of CAP of mild to moderate severity, as a result of severe hepatic toxicity associated with its use,^[122] and that neither a paediatric dosage nor an intravenous formulation are available so far.

3. New Drugs in Development for *S. pneumoniae* Infections

Because of the increasing problem of MDR in Gram-positive organisms, research of new molecules with improved activity on methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant enterococci and MDR pneumococci has been very active over recent years.^[194] Table IV shows

Table VIII. Current therapeutic recommendations for meningitis caused by multidrug-resistant or non-multidrug-resistant *Streptococcus pneumoniae*^[171]

Phenotype	Antibacterial	Dosage
PenS	Benzylpenicillin (penicillin G)	4 × 10 ⁶ U IV every 4h
PenI, cephalosporin S	Cefotaxime	2g IV every 4–6h
	Ceftriaxone	2g IV every 12h
Cephalosporin I-R	Vancomycin +	15 mg/kg IV every 8–12h
	Cefotaxime or	2g IV every 4–6h
	Ceftriaxone	2g IV every 12h

I-R = intermediate to resistant; **IV** = intravenous; **PenI** = penicillin intermediate; **PenS** = penicillin sensitive; **S** = sensitive.

the *in vitro* activity of these drugs against pneumococci.

Of note is that all of these molecules, with the exception of deformylase inhibitors, are new derivatives within existing classes of drugs, which have been selected based on improved intrinsic activity. Some of these derivatives are claimed to remain unaffected by existing resistance mechanisms, which is partially true for molecules that possess new modes of action (i.e. new glycopeptides vs vancomycin)^[195] and/or new binding sites in the bacterial target (i.e. ketolides vs macrolides).^[196] For other families, new derivatives are less susceptible to some resistance mechanisms. This is for instance well described for resistance mediated by efflux pumps, which extrude old quinolones or macrolides more efficiently than new quinolones or ketolides,^[197] or for tetracycline resistance mediated by ribosomal protection, which does not affect glycyclines.^[198] This is not surprising, since susceptibility to known resistance mechanisms is an integral part of the criteria included in the selection process of new antibacterials for further development. However, in most cases, the emergence of cross-resistance remains inevitable, even though it is not detected by performing MIC determinations, simply because the activity of the drug is so high, even when measured in isolates resistant to the parent compounds, that MIC values remain far below the susceptibility breakpoint. This is well exemplified for new quinolones, which remain active on first-step mutants in topoisomerases.^[199,200]

Also of note is that most of these compounds have primarily been designed and selected for an anti-MRSA activity, and proved active against *S. pneumoniae* only during systematic *in vitro* screening. This is probably the consequence of the apparently still satisfying efficacy of current therapeutic options for treating MDR pneumococcal infections (see section 2.3), but the picture may change in a near future.

Focusing on molecules that are now in clinical development and have respiratory tract infections in their target indications, table V summarises the pharmacokinetic data and suggests pharmacodynamic breakpoints. Globally speaking, this table shows that the proposed dosage of all these drugs allows for the pharmacodynamic criteria of efficacy

for 90% of the strains susceptible to the parent compounds, and for at least 50% of intermediate or resistant strains to be met.

Within the class of β -lactams, ceftobiprole, ceftaroline and RWJ-54428 are cephalosporins specifically designed to keep activity against MRSA as a result of an increased affinity for PBP2a.^[201] Cefditoren is not active against MRSA. These drugs also show low MIC values against *S. pneumoniae*, including penicillin-intermediate or resistant strains (table IV). Cefditoren has low MIC values but also low time>MIC levels and is also highly protein bound, with correspondingly inappropriate coverage of penicillin non-susceptible strains. Ceftobiprole (as its medocaril prodrug) is currently in phase III trials for complicated skin and skin-structure infections and nosocomial pneumonia due to suspected or proven MRSA, as well as for CAP. The later indication is based on its efficacy at low doses in animal models of pneumonia.^[202] The US FDA has granted fast-track status to the compound for these two indications and phase III trial results should be soon available.^[203] Ceftaroline (as its fosamil prodrug) is currently being evaluated only for MRSA skin and soft-tissue infections. Both ceftobiprole medocaril and ceftaroline fosamil are limited by having only an intravenous formulation, which restricts their use to hospital. In contrast, cefmatilen is intended for oral administration. Similarly, faropenem medoxomil is an oral carbapenem, which rather directs it towards community usage. Accordingly, it has been evaluated in bacterial rhinosinusitis where 7 days' treatment showed equivalence or superiority to 10 days' treatment with cefuroxime axetil, with fewer gastrointestinal adverse effects than amoxicillin/clavulanic acid.^[152] This drug may prove a useful alternative to current β -lactams; however, it would require specific examination of activity against resistant strains and other indications such as CAP.

New glycopeptides have been designed to keep activity against vancomycin-resistant enterococci and staphylococci. Their capacity to interact and to destabilise the bacterial membrane confers them with a highly bactericidal potential towards Gram-positive organisms.^[195] However, at the present time, and despite low MIC values against pneumococci (table IV), these drugs are currently in development for MRSA infections only, including hospi-

tal-acquired pneumonia for telavancin. The same development plan holds true for linezolid, which proved efficient against pneumococci, but is indicated only for MRSA infections. However, phase III studies have been performed in CAP, where the drug proved as effective as cephalosporins, with a trend to superior clinical cure rate in patients with bacteraemia.^[204,205]

The role of macrolides in pneumococcal infections is severely restricted by the increasing rate of resistance, but ketolides may offer an appropriate alternative, in the sense that they are less affected than conventional macrolides by the most common resistance mechanisms.^[6] Thus, their dual-binding site in the ribosome (domains II and V of 23S RNA) allows them to bind with sufficient affinity to ribosomes mutated in the unique binding site (domain V) of conventional macrolides and to impair protein synthesis.^[196] They are also poor substrates of macrolide efflux pumps.^[206] The development of resistance to ketolides has long been considered as unlikely in terms of fitness cost (are two mutations within a single target viable?).^[207] Nevertheless, case reports are beginning to appear all over the world,^[208-210] indicating that prudent use is the rule, as for any antimicrobial. Other pros and cons to balance for these drugs are on the one hand, a concomitant activity against intracellular pathogens, which may be useful in empirical therapy, but on the other hand, a severe hepatic toxicity, which recently led the FDA to restrict the indications of telithromycin to CAP.^[122] This point will certainly be examined with caution for forthcoming ketolides such as cethromycin.

Even though not registered in this indication, tigecycline might become one alternative of choice for MDR pneumococci. Like most cephalosporins, it can be administered by the intravenous route only.^[164] The absence of cross-resistance with currently available anti-pneumococcal or anti-MRSA antibacterials pushed the FDA to authorise the off-label use of this drug for MDR pneumonia. New compounds, such as MK 2764 (PTK 0796), are being developed as oral and intravenous formulations

in parallel,^[211] which will extend the indications to non-hospitalised patients.

The quinolones represent the class of drugs for which respiratory tract infections are in the forefront of target indications. In this context, the main interesting properties of new fluoroquinolones consist of: (i) once-daily administration; (ii) easy parenteral-oral switch as a result of excellent bioavailability; (iii) spectrum of activity covering bacteria responsible for typical and atypical pneumonia; and (iv) a rapid bactericidal effect. However, several drawbacks temper these advantages. First, they possess a broad spectrum of activity, so that their use will be associated with flora disturbance and selection of resistance in streptococci as well as other bacterial species. Second, these drugs can induce a series of severe adverse effects,² which have been associated with restriction of use or total withdrawal of many representatives in the class.^[212] The most recent voluntary withdrawals following FDA warnings concern grepafloxacin (cardiovascular events^[213]), and gatifloxacin (hypo- and hyperglycaemia^[214-216]) and the most recent restricted use was trovafloxacin (hepatotoxicity^[217,218]). Third, fluoroquinolones are associated with a number of drug interactions, which either alter the pharmacokinetics of the fluoroquinolone or of the co-administered drug, or increase the risk of adverse effects.^[165,212] On these bases, one can easily understand that the development of new fluoroquinolones goes through a careful and early evaluation of their safety profile, causing the arrest of the development of many promising compounds.

4. Conclusion

Currently, the management of infections caused by MDR pneumococci can still continue to be based on use of classical antibacterial choices (β -lactams, ketolides, fluoroquinolones). The success rate will be determined by the correct appraisal of pharmacodynamic parameters, which involve not only the use of appropriate dosages, but also the selection of the more potent agents in the class.

However, in a world of active research, where new, highly potent molecules will soon arrive on the

2 The issue of quinolone toxicity is so topical that a website (<http://www.fqresearch.org/index.htm>) is devoted to the follow-up of adverse events and changes brought to package inserts as a consequence of pharmacovigilance studies.

market, a burning question concerns the place these molecules could occupy in our future therapeutic arsenal.^[219] As long as the total antimicrobial consumption stays flat, these new antibacterials would reduce the utilisation of current drugs, and hence, avoid further increase in resistance. But a non-negligible risk exists that the introduction of new molecules renews the confidence of clinicians in the success of antibacterial therapy and stimulates their wide-scale use, which will unavoidably lead to the development of new resistance mechanisms.

Vaccination remains an interesting alternative to reduce the risk of developing infection; however, the limitation of this approach consists in the difficulty to include the most prevalent serotypes, which can result in the selection of non-vaccinal MDR clones.

Acknowledgements

Dr Van Bambeke is Maître de Recherches of the Belgian Fonds de la Recherche Scientifique - Fonds National de la Recherche Scientifique. Dr Van Bambeke has acted as a consultant to Targanta, Dr Reinert has received honoraria for consultancies from Wyeth and GSK, and a research grant from Wyeth. Drs Appelbaum, Tulkens and Peetermans have no conflicts of interest that are directly relevant to the content of this review. No sources of funding were used to assist in the preparation of this review.

References

- Musher DM. Infections caused by *Streptococcus pneumoniae*: clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis 1992 Apr; 14 (4): 801-7
- Ortqvist A, Hedlund J, Kalin M. *Streptococcus pneumoniae*: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med 2005 Dec; 26 (6): 563-74
- Appelbaum PC. Resistance among *Streptococcus pneumoniae*: implications for drug selection. Clin Infect Dis 2002 Jun 15; 34 (12): 1613-20
- Lynch III JP, Zhanel GG. Escalation of antimicrobial resistance among *Streptococcus pneumoniae*: implications for therapy. Semin Respir Crit Care Med 2005 Dec; 26 (6): 575-616
- Hakenbeck R, Briese T, Chalkley L, et al. Antigenic variation of penicillin-binding proteins from penicillin-resistant clinical strains of *Streptococcus pneumoniae*. J Infect Dis 1991 Aug; 164 (2): 313-9
- Reinert RR. Clinical efficacy of ketolides in the treatment of respiratory tract infections. J Antimicrob Chemother 2004 Jun; 53 (6): 918-27
- Sutcliffe J, Tait-Kamradt A, Wondrack L. *Streptococcus pneumoniae* and *Streptococcus pyogenes* resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996 Aug; 40 (8): 1817-24
- Canu A, Malbrun B, Coquemont M, et al. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in *Streptococcus pneumoniae*. Antimicrob Agents Chemother 2002 Jan; 46 (1): 125-31
- Depardieu F, Courvalin P. Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in *Streptococcus pneumoniae*. Antimicrob Agents Chemother 2001 Jan; 45 (1): 319-23
- Reinert RR, Wild A, Appelbaum P, et al. Ribosomal mutations conferring resistance to macrolides in *Streptococcus pneumoniae* clinical strains isolated in Germany. Antimicrob Agents Chemother 2003 Jul; 47 (7): 2319-22
- Tait-Kamradt A, Davies T, Cronan M, et al. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 2000 Aug; 44 (8): 2118-25
- Pan XS, Ambler J, Mehtar S, et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in *Streptococcus pneumoniae*. Antimicrob Agents Chemother 1996 Oct; 40 (10): 2321-6
- Jones ME, Critchley IA, Karlosky JA, et al. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of *Staphylococcus aureus* and *Streptococcus pneumoniae* with defined mutations in DNA gyrase and topoisomerase IV. Antimicrob Agents Chemother 2002 Jun; 46 (6): 1651-7
- Van Bambeke F, Michot JM, Van Eldere J, et al. Quinolones in 2005: an update. Clin Microbiol Infect 2005 Apr; 11 (4): 256-80
- Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, *pmrA*, associated with fluoroquinolone resistance in *Streptococcus pneumoniae*. Antimicrob Agents Chemother 1999 Jan; 43 (1): 187-9
- Marrer E, Schad K, Satoh AT, et al. Involvement of the putative ATP-dependent efflux proteins PatA and PatB in fluoroquinolone resistance of a multidrug-resistant mutant of *Streptococcus pneumoniae*. Antimicrob Agents Chemother 2006 Feb; 50 (2): 685-93
- Coffey TJ, Dowson CG, Daniels M, et al. Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of *Streptococcus pneumoniae*. Mol Microbiol 1991 Sep; 5 (9): 2255-60
- Widdowson CA, Klugman KP. Molecular mechanisms of resistance to commonly used non-beta-lactam drugs in *Streptococcus pneumoniae*. Semin Respir Infect 1999 Sep; 14 (3): 255-68
- Syrogianopoulos GA, Grivea IN, Tait-Kamradt A, et al. Identification of an *erm(A)* erythromycin resistance methylase gene in *Streptococcus pneumoniae* isolated in Greece. Antimicrob Agents Chemother 2001 Jan; 45 (1): 342-4
- Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004 Oct 1; 39 (7): 1010-5
- Clinical and Laboratory Standards Institute. CLSI guidelines [online]. Available from URL: http://www.clsi.org/source/orders/index.cfm?section=Shop&task=3&CATEGORY=MI&PRODUCT_TYPE=SALES&SKU=M100S17E [Accessed 2007 Sep 11]
- European Committee on Antimicrobial Susceptibility Testing [online]. Available from URL: <http://www.escmid.org> [Accessed 2007 Sep 11]
- Schurek KN, Adam HJ, Hoban DJ, et al. Call for the international adoption of microbiological breakpoints for fluoroquinolones and *Streptococcus pneumoniae*. Int J Antimicrob Agents 2006 Sep; 28 (3): 266-9
- Kariuki S, Muyodi J, Mirza B, et al. Antimicrobial susceptibility in community-acquired bacterial pneumonia in adults. East Afr Med J 2003 Apr; 80 (4): 213-7
- Valles X, Flannery B, Roca A, et al. Serotype distribution and antibiotic susceptibility of invasive and nasopharyngeal isolates of *Streptococcus pneumoniae* among children in rural Mozambique. Trop Med Int Health 2006 Mar; 11 (3): 358-66

26. Liebowitz LD, Slabbert M, Huisamen A. National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents. *J Clin Pathol* 2003 May; 56 (5): 344-7
27. Schito GC, Felmingham D. Susceptibility of *Streptococcus pneumoniae* to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003). *Int J Antimicrob Agents* 2005 Dec; 26 (6): 479-85
28. Mendes C, Marin ME, Quinones F, et al. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000). *Braz J Infect Dis* 2003 Feb; 7 (1): 44-61
29. Canton R, Morosini M, Enright MC, et al. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant *Streptococcus pneumoniae*: data from the global PROTEKT surveillance programme. *J Antimicrob Chemother* 2003 Dec; 52 (6): 944-52
30. Bonfiglio L, Ojeda MI, de Mier C, et al. Phenotypic and genotypic characterization of macrolide resistant *Streptococcus pneumoniae* recovered from adult patients with community-acquired pneumonia in an Argentinian teaching hospital. *Int J Antimicrob Agents* 2005 Mar; 25 (3): 260-3
31. Koeth LM, Felmingham D, Jacobs MR, et al. Antimicrobial resistance of *Streptococcus pneumoniae* and *Haemophilus influenzae* in Sao Paulo, Brazil from 1996 to 2000. *Int J Antimicrob Agents* 2004 Apr; 23 (4): 356-61
32. Ochoa TJ, Rupa R, Guerra H, et al. Penicillin resistance and serotypes/serogroups of *Streptococcus pneumoniae* in nasopharyngeal carrier children younger than 2 years in Lima, Peru. *Diagn Microbiol Infect Dis* 2005 May; 52 (1): 59-64
33. Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in respiratory tract *Streptococcus pneumoniae* isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. *Antimicrob Agents Chemother* 2003 Jun; 47 (6): 1867-74
34. Powis J, McGeer A, Green K, et al. In vitro antimicrobial susceptibilities of *Streptococcus pneumoniae* clinical isolates obtained in Canada in 2002. *Antimicrob Agents Chemother* 2004 Sep; 48 (9): 3305-11
35. Jenkins SG, Farrell DJ, Patel M, et al. Trends in anti-bacterial resistance among *Streptococcus pneumoniae* isolated in the USA, 2000-2003: PROTEKT US years 1-3. *J Infect* 2005 Dec; 51 (5): 355-63
36. Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among *Streptococcus pneumoniae* in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? *Clin Infect Dis* 2005 Jul 15; 41 (2): 139-48
37. Draghi DC, Jones ME, Sahm DF, et al. Geographically-based evaluation of multidrug resistance trends among *Streptococcus pneumoniae* in the USA: findings of the FAST surveillance initiative (2003-2004). *Int J Antimicrob Agents* 2006 Dec; 28 (6): 525-31
38. Ho PL, Que TL, Chiu SS, et al. Fluoroquinolone and other antimicrobial resistance in invasive pneumococci, Hong Kong, 1995-2001. *Emerg Infect Dis* 2004 Jul; 10 (7): 1250-7
39. Yamaguchi K, Ohno A. Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002. *Diagn Microbiol Infect Dis* 2005 Jun; 52 (2): 135-43
40. Inoue M, Kaneko K, Akizawa K, et al. Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-3 (1999-2002). *J Infect Chemother* 2006 Feb; 12 (1): 9-21
41. Oishi K, Yoshimine H, Watanabe H, et al. Drug-resistant genes and serotypes of pneumococcal strains of community-acquired pneumonia among adults in Japan. *Respirology* 2006 Jul; 11 (4): 429-36
42. Chiba N, Kobayashi R, Hasegawa K, et al. Antibiotic susceptibility according to genotype of penicillin-binding protein and macrolide resistance genes, and serotype of *Streptococcus pneumoniae* isolates from community-acquired pneumonia in children. *J Antimicrob Chemother* 2005 Oct; 56 (4): 756-60
43. Stratchounski LS, Kozlov RS, Appelbaum PC, et al. Antimicrobial resistance of nasopharyngeal pneumococci from children from day-care centres and orphanages in Russia: results of a unique prospective multicentre study. *Clin Microbiol Infect* 2006 Sep; 12 (9): 853-66
44. Lin WJ, Lo WT, Chou CY, et al. Antimicrobial resistance patterns and serotype distribution of invasive *Streptococcus pneumoniae* isolates from children in Taiwan from 1999 to 2004. *Diagn Microbiol Infect Dis* 2006 Oct; 56 (2): 189-96
45. Greenberg D, Dagan R, Muallem M, et al. Antibiotic-resistant invasive pediatric *Streptococcus pneumoniae* clones in Israel. *J Clin Microbiol* 2003 Dec; 41 (12): 5541-5
46. Memish ZA, Balkhy HH, Shibl AM, et al. *Streptococcus pneumoniae* in Saudi Arabia: antibiotic resistance and serotypes of recent clinical isolates. *Int J Antimicrob Agents* 2004 Jan; 23 (1): 32-8
47. Buxbaum A, Forsthuber S, Sauermann R, et al. Development of macrolide-resistance and comparative activity of telithromycin in streptococci in Austria, 1996-2002. *Int J Antimicrob Agents* 2004 Oct; 24 (4): 397-400
48. Rendi-Wagner P, Georgopoulos A, Kundi M, et al. Prospective surveillance of incidence, serotypes and antimicrobial susceptibility of invasive *Streptococcus pneumoniae* among hospitalized children in Austria. *J Antimicrob Chemother* 2004 May; 53 (5): 826-31
49. Reinert RR, Reinert S, van der LM, et al. Antimicrobial susceptibility of *Streptococcus pneumoniae* in eight European countries from 2001 to 2003. *Antimicrob Agents Chemother* 2005 Jul; 49 (7): 2903-13
50. Van Eldere J, Meekers E, Lagrou K, et al. Macrolide-resistance mechanisms in *Streptococcus pneumoniae* isolates from Belgium. *Clin Microbiol Infect* 2005 Apr; 11 (4): 332-4
51. Vanhoof R, Carpentier M, Cartuyvels R, et al. Surveillance of antibiotic resistance in non invasive clinical isolates of *Streptococcus pneumoniae* collected in Belgium during winters 2003 and 2004. *Acta Clin Belg* 2006 Mar; 61 (2): 49-57
52. Altraja A, Naaber P, Tamm E, et al. Antimicrobial susceptibility of common pathogens from community-acquired lower respiratory tract infections in Estonia. *J Chemother* 2006 Dec; 18 (6): 603-9
53. Pihlajamäki M, Jalava J, Huovinen P, et al. Antimicrobial resistance of invasive pneumococci in Finland in 1999-2000. *Antimicrob Agents Chemother* 2003 Jun; 47 (6): 1832-5
54. Bergman M, Huikko S, Huovinen P, et al. Macrolide and azithromycin use are linked to increased macrolide resistance in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2006 Nov; 50 (11): 3646-50
55. Rantala M, Huikko S, Huovinen P, et al. Prevalence and molecular genetics of macrolide resistance among *Streptococcus pneumoniae* isolates collected in Finland in 2002. *Antimicrob Agents Chemother* 2005 Oct; 49 (10): 4180-4
56. Decousser JW, Pina P, Viguier F, et al. Invasive *Streptococcus pneumoniae* in France: antimicrobial resistance, serotype, and molecular epidemiology findings from a monthly national study in 2000 to 2002. *Antimicrob Agents Chemother* 2004 Sep; 48 (9): 3636-9
57. Reinert RR, Simic S, Al Lahham A, et al. Antimicrobial resistance of *Streptococcus pneumoniae* recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study. *J Clin Microbiol* 2001 Mar; 39 (3): 1187-9

58. Reinert RR, van der Linden M, Al-Lahham A, et al. Molecular epidemiology of penicillin-resistant *Streptococcus pneumoniae* isolated from children with invasive pneumococcal disease in Germany. Clin Microbiol Infect 2007 Apr; 13 (4): 363-8
59. Ioannidou S, Tassios PT, Zachariadou L, et al. In vitro activity of telithromycin (HMR 3647) against Greek *Streptococcus pyogenes* and *Streptococcus pneumoniae* clinical isolates with different macrolide susceptibilities. Clin Microbiol Infect 2003 Jul; 9 (7): 704-7
60. Dobay O, Rozgonyi F, Hajdu E, et al. Antibiotic susceptibility and serotypes of *Streptococcus pneumoniae* isolates from Hungary. J Antimicrob Chemother 2003 Apr; 51 (4): 887-93
61. Buseti M, Longo B, Campello C. Low rates of antimicrobial resistance in respiratory pathogens from a pediatric population in north-eastern Italy. Pediatr Med Chir 2003 Mar; 25 (2): 131-4
62. Boccia D, D'Ancona F, Salmaso S, et al. Antibiotic-resistance in Italy: activity of the first year of the surveillance project AR-ISS [in Italian]. Ann Ig 2005 Mar; 17 (2): 95-110
63. Marchese A, Gualco L, Cochetti I, et al. Antibiotic susceptibility and serotype distribution in *Streptococcus pneumoniae* circulating in Italy: results of the SEMPRES surveillance study (2000-2002). Int J Antimicrob Agents 2005 Aug; 26 (2): 138-45
64. Deshpande LM, Sader HS, Debbia E, et al. Emergence and epidemiology of fluoroquinolone-resistant *Streptococcus pneumoniae* strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004). Diagn Microbiol Infect Dis 2006 Mar; 54 (3): 157-64
65. Littauer P, Sangvik M, Caugant DA, et al. Molecular epidemiology of macrolide-resistant isolates of *Streptococcus pneumoniae* collected from blood and respiratory specimens in Norway. J Clin Microbiol 2005 May; 43 (5): 2125-32
66. Sadowy E, Izdebski R, Skoczynska A, et al. Phenotypic and molecular analysis of penicillin-nonsusceptible *Streptococcus pneumoniae* isolates in Poland. Antimicrob Agents Chemother 2007 Jan; 51 (1): 40-7
67. Melo-Cristino J, Ramirez M, Serrano N, et al. Macrolide resistance in *Streptococcus pneumoniae* isolated from patients with community-acquired lower respiratory tract infections in Portugal: results of a 3-year (1999-2001) multicenter surveillance study. Microb Drug Resist 2003; 9 (1): 73-80
68. Dias R, Louro D, Canica M. Antimicrobial susceptibility of invasive *Streptococcus pneumoniae* isolates in Portugal over an 11-year period. Antimicrob Agents Chemother 2006 Jun; 50 (6): 2098-105
69. Cizman M, Beovic B, Seme K, et al. Macrolide resistance rates in respiratory pathogens in Slovenia following reduced macrolide use. Int J Antimicrob Agents 2006 Dec; 28 (6): 537-42
70. Valles X, Marcos A, Pinart M, et al. Hospitalized community-acquired pneumonia due to *Streptococcus pneumoniae*: has resistance to antibiotics decreased? Chest 2006 Sep; 130 (3): 800-6
71. Perez-Trallero E, Garcia-de-la-Fuente C, Garcia-Rey C, et al. Geographical and ecological analysis of resistance, co-resistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005 May; 49 (5): 1965-72
72. Neeleman C, De Valk JA, Klaassen CH, et al. In-vitro susceptibility and molecular characterisation of macrolide resistance mechanisms among *Streptococcus pneumoniae* isolates in The Netherlands: the DUEL 2 study. Clin Microbiol Infect 2005 Apr; 11 (4): 312-8
73. Sener B, Koseoglu O, Fisen I, et al. *Streptococcus pneumoniae* strains resistance to macrolide, lincosamide, streptogramin, oxazolidinone and ketolide [in Turkish]. Mikrobiyol Bul 2002 Apr; 36 (2): 125-31
74. Sener B, Koseoglu O, Gur D, et al. Mechanisms of macrolide resistance in clinical pneumococcal isolates in a university hospital, Ankara, Turkey. J Chemother 2005 Feb; 17 (1): 31-5
75. Gazi H, Kurutepe S, Surucuoglu S, et al. Antimicrobial susceptibility of bacterial pathogens in the oropharynx of healthy school children in Turkey. Indian J Med Res 2004 Nov; 120 (5): 489-94
76. Shackcloth J, Williams L, Farrell DJ. *Streptococcus pneumoniae* and *Streptococcus pyogenes* isolated from a paediatric population in Great Britain and Ireland: the in vitro activity of telithromycin versus comparators. J Infect 2004 Apr; 48 (3): 229-35
77. Gosbell IB, Fernandes LA, Fernandes CJ. In vitro antibacterial activity of beta-lactams and non-beta-lactams against *Streptococcus pneumoniae* isolates from Sydney, Australia. Pathology 2006 Aug; 38 (4): 343-8
78. Felmingham D, Reinert RR, Hirakata Y, et al. Increasing prevalence of antimicrobial resistance among isolates of *Streptococcus pneumoniae* from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002 Sep; 50 Suppl. S1: 25-37
79. Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003 Aug; 52 (2): 229-46
80. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J Antimicrob Chemother 2000 Jul; 46 Suppl. T1: 3-9
81. Fluit AC, Jones ME, Schmitz FJ, et al. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000 Mar; 30 (3): 454-60
82. Gordon KA, Biedenbach DJ, Jones RN. Comparison of *Streptococcus pneumoniae* and *Haemophilus influenzae* susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003 Aug; 46 (4): 285-9
83. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant *Streptococcus pneumoniae* in the United States. N Engl J Med 2000 Dec 28; 343 (26): 1917-24
84. Bartlett JG, Breiman RF, Mandell LA, et al. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis 1998 Apr; 26 (4): 811-38
85. Kam KM, Luey KY, Fung SM, et al. Emergence of multiple-antibiotic-resistant *Streptococcus pneumoniae* in Hong Kong. Antimicrob Agents Chemother 1995 Dec; 39 (12): 2667-70
86. Rahman M, Hossain S, Shoma S, et al. Emergence of a unique multiply-antibiotic-resistant *Streptococcus pneumoniae* serotype 7B clone in Dhaka, Bangladesh. J Clin Microbiol 2006 Dec; 44 (12): 4625-7
87. Song JH, Yang JW, Jin JH, et al. Molecular characterization of multidrug-resistant *Streptococcus pneumoniae* isolates in Korea: the Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group. J Clin Microbiol 2000 Apr; 38 (4): 1641-4
88. Song JH, Yang JW, Peck KR, et al. Spread of multidrug-resistant *Streptococcus pneumoniae* in South Korea. Clin Infect Dis 1997 Sep; 25 (3): 747-9
89. Time magazine. Menace from South Africa [online]. Available from URL: <http://www.time.com/time/magazine/article/0,9171,915505,00.html> [Accessed 2007 Mar 8]
90. Reinert RR. Resistance phenotypes and multi-drug resistance in *Streptococcus pneumoniae* (PROTEKT years 1-3 [1999-2001]). J Chemother 2004 Dec; 16 Suppl. 6: 35-48

91. Reinert RR, Jacobs MR, Appelbaum PC, et al. Relationship between the original multiply resistant South African isolates of *Streptococcus pneumoniae* from 1977 to 1978 and contemporary international resistant clones. *J Clin Microbiol* 2005 Dec; 43 (12): 6035-41
92. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. *Proc Natl Acad Sci U S A* 1998 Mar 17; 95 (6): 3140-5
93. Enright MC, Spratt BG. A multilocus sequence typing scheme for *Streptococcus pneumoniae*: identification of clones associated with serious invasive disease. *Microbiology* 1998 Nov; 144 (Pt 11): 3049-60
94. Reinert RR. Pneumococcal conjugate vaccines: a European perspective. *Int J Med Microbiol* 2004 Oct; 294 (5): 277-94
95. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant *Streptococcus pneumoniae*. *N Engl J Med* 2006 Apr 6; 354 (14): 1455-63
96. Pai R, Moore MR, Pilishvili T, et al. Postvaccine genetic structure of *Streptococcus pneumoniae* serotype 19A from children in the United States. *J Infect Dis* 2005 Dec 1; 192 (11): 1988-95
97. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. *JAMA* 2007 Apr 25; 297 (16): 1784-92
98. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. *Eur Respir J* 2005 Dec; 26 (6): 1138-80
99. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of america/american thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2007 Mar 1; 44 Suppl. 2: S27-72
100. Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. *Am J Respir Crit Care Med* 2000 Jul; 162 (1): 154-60
101. Tleyjeh IM, Tlayeh HM, Hejal R, et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. *Clin Infect Dis* 2006 Mar 15; 42 (6): 788-97
102. Falco V, Almirante B, Jordano Q, et al. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains? *J Antimicrob Chemother* 2004 Aug; 54 (2): 481-8
103. Moroney JF, Fiore AE, Harrison LH, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. *Clin Infect Dis* 2001 Sep 15; 33 (6): 797-805
104. Song JH, Jung SI, Ki HK, et al. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. *Clin Infect Dis* 2004 Jun 1; 38 (11): 1570-8
105. Falagas ME, Siempos II, Bliziotis IA, et al. Impact of initial discordant treatment with beta-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review. *Mayo Clin Proc* 2006 Dec; 81 (12): 1567-74
106. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. *Clin Infect Dis* 2003 Jul 15; 37 (2): 230-7
107. Garau J. Treatment of drug-resistant pneumococcal pneumonia. *Lancet Infect Dis* 2002 Jul; 2 (7): 404-15
108. Klugman KP, Low DE, Metlay J, et al. Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities. *Int J Antimicrob Agents* 2004 Nov; 24 (5): 411-22
109. Chiou CC, Yu VL. Severe pneumococcal pneumonia: new strategies for management. *Curr Opin Crit Care* 2006 Oct; 12 (5): 470-6
110. Kosowska K, Hoellman DB, Lin G, et al. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. *Antimicrob Agents Chemother* 2005 May; 49 (5): 1932-42
111. Fenoll A, Gimenez MJ, Robledo O, et al. Activity of cefditoren against clinical isolates of *Streptococcus pneumoniae* showing non-susceptibility to penicillins, cephalosporins, macrolides, ketolides or quinolones. *Int J Antimicrob Agents* 2007 Feb; 29 (2): 224-6
112. Hoffman-Roberts HL, Babcock C, Mitropoulos IF. Investigational new drugs for the treatment of resistant pneumococcal infections. *Expert Opin Investig Drugs* 2005 Aug; 14 (8): 973-95
113. Tsuji M, Ishii Y, Ohno A, et al. In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin. *Antimicrob Agents Chemother* 1995 Nov; 39 (11): 2544-51
114. Sader HS, Deshpande LM, Jones RN. Antimicrobial activity and spectrum of PPI-0903 (TAK-599) a novel cephalosporin, tested against a worldwide collection of clinical strains [abstract no. F-325]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 1; Washington, DC
115. Koga T, Abe T, Inoue H, et al. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. *Antimicrob Agents Chemother* 2005 Aug; 49 (8): 3239-50
116. Candiani G, Abboni M, Borroni M, et al. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. *J Antimicrob Chemother* 1999 Aug; 44 (2): 179-92
117. King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. *J Antimicrob Chemother* 2004 May; 53 (5): 797-803
118. Piper KE, Steckelberg JM, Patel R. In vitro activity of daptomycin against clinical isolates of Gram-positive bacteria. *J Infect Chemother* 2005 Aug; 11 (4): 207-9
119. Dugourd D, Siu R, Fenn J, et al. In vitro characterization of MX-2401: a novel amphotericin derivative active against Gram-positive bacteria. [abstract no. FI-1879]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
120. Mason Jr EO, Lamberth LB, Wald ER, et al. In vitro activities of cethromycin (ABT-773), a new ketolide, against *Streptococcus pneumoniae* strains that are not susceptible to penicillin or macrolides. *Antimicrob Agents Chemother* 2003 Jan; 47 (1): 166-9
121. Shortridge VD, Zhong P, Cao Z, et al. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci. *Antimicrob Agents Chemother* 2002 Mar; 46 (3): 783-6
122. Food and Drug Administration. FDA announces label and indication changes for the antibiotic ketek [online]. Available from URL: <http://www.fda.gov/cder/drug/infopage/telithromycin/default.htm> [Accessed 2007 Feb 28]
123. Phan LT, Polemopoulos A, Wang G, et al. In vitro antibacterial activity of EDP-420, a new bridged bicyclic macrolide [abstract no. E-1858]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)

124. Sugiyama H, Suzuki K, Nanaumi K, et al. FMA-1485, a novel 2-fluoroketolide: in vitro and in vivo antibacterial activity against respiratory tract pathogens [abstract no. F1-1485]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
125. Jones RN, Sader HS, Fritsche TR. Activity of VIC-105555 (VIC), a novel lincosamide, tested against Gram-positive bacteria and anaerobes [abstract no. F-2040]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16-19; Washington, DC
126. Reinert RR, Kresken M, Mechery V, et al. In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant *Streptococcus pneumoniae*. Eur J Clin Microbiol Infect Dis 1998 Sep; 17 (9): 662-5
127. Hoellman DB, Lin G, Ednie LM, et al. Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents. Antimicrob Agents Chemother 2003 Mar; 47 (3): 1148-50
128. Traczewski MM, Brown SD. Potency and spectrum of activity compared to ten other antimicrobial compounds [abstract no. F-753]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago (IL)
129. Weir S, Maccone A, Donatelli J, et al. The activity of PTK 0796 against tetracycline resistance [abstract no. F-752]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago (IL)
130. Kosowska-Shick K, Credito K, Pankuch GA, et al. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. Antimicrob Agents Chemother 2006 Jun; 50 (6): 2064-71
131. Pankuch GA, Nagai K, Davies TA, et al. Antipneumococcal activity of BMS 284756 compared to those of six other agents. Antimicrob Agents Chemother 2002 Jan; 46 (1): 251-4
132. Al Lahham A, De Souza NJ, Patel M, et al. Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of *Streptococcus pneumoniae* and *Streptococcus pyogenes*. J Antimicrob Chemother 2005 Dec; 56 (6): 1130-3
133. Wickman PA, Black JA, Moland ES, et al. In vitro activities of DX-619 and comparison quinolones against gram-positive cocci. Antimicrob Agents Chemother 2006 Jun; 50 (6): 2255-7
134. Wickman PA, Moland ES, Black JA, et al. In vitro activity of DX-619, a novel des-fluoro(6) quinolone, against a panel of *Streptococcus pneumoniae* mutants with characterized resistance mechanisms. Antimicrob Agents Chemother 2006 Feb; 50 (2): 796-8
135. Browne FA, Bozdogan B, Clark C, et al. Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents. Antimicrob Agents Chemother 2003 Dec; 47 (12): 3815-24
136. Jones RN, Sader HS, Fritsche TR. DC-159a, a novel oral quinolone, activity tested against community-acquired respiratory tract (CA-RTI) pathogens [abstract no. F1-480]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
137. Adam HJ, Schurek KN, Decorbey MR, et al. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical *Streptococcus pneumoniae* isolates, including molecularly characterized ciprofloxacin-resistant isolates. J Antimicrob Chemother 2006 Jul; 58 (1): 202-4
138. Watanabe A, Tokue Y, Takahashi H, et al. In vitro activity of HSR-903, a new oral quinolone, against bacteria causing respiratory infections. Antimicrob Agents Chemother 1999 Jul; 43 (7): 1767-8
139. Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 2003 Dec 1; 13 (23): 4217-21
140. Jacobs MR, Good CE, Windau A, et al. AR-709, A novel diaminopyrimidine compound: activity against *Streptococcus pneumoniae* [abstract no. F1-1956]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
141. Ednie LM, Pankuch G, Appelbaum PC. Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob Agents Chemother 2004 Oct; 48 (10): 4027-32
142. Suarez-Kurtz G, Ribeiro FM, Vicente FL, et al. Development and validation of limited-sampling strategies for predicting amoxicillin pharmacokinetic and pharmacodynamic parameters. Antimicrob Agents Chemother 2001 Nov; 45 (11): 3029-36
143. Andes D, Craig WA. Understanding pharmacokinetics and pharmacodynamics: application to the antimicrobial formulary decision process. In: Owens RC, Ambrose PG, Nightingale CH, editors. Antibiotic optimization: concepts and strategies in clinical practice. New York: Marcel Dekker, 2005: 65-88
144. Spyker DA, Rugloski RJ, Vann RL, et al. Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration. Antimicrob Agents Chemother 1977 Jan; 11 (1): 132-41
145. Chen RR, Lee TY, Hsieh WC. Effect of food on pharmacokinetics of cefuroxime axetil in Chinese subjects. J Formos Med Assoc 1992 Dec; 91 (12): 1177-81
146. Patel IH, Chen S, Parsonnet M, et al. Pharmacokinetics of ceftiraxone in humans. Antimicrob Agents Chemother 1981 Nov; 20 (5): 634-41
147. Kemmerich B, Lode H, Belmega G, et al. Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother 1983 Mar; 23 (3): 429-34
148. Li JT, Hou F, Lu H, et al. Phase I clinical trial of cefditoren pivoxil (ME 1207): pharmacokinetics in healthy volunteers. Drugs Exp Clin Res 1997; 23 (5-6): 145-50
149. Schmitt-Hoffmann A, Roos B, Schleimer M, et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004 Jul; 48 (7): 2570-5
150. Ge Y, Hubbel A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPP-0903) [abstract no. A-1935]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
151. Ge Y, Redman R, Floren L, et al. The pharmacokinetics and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous infusions [abstract no. A-1937]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
152. Hadley JA, Tillotson GS, Tosiello R, et al. Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis. Expert Rev Anti Infect Ther 2006 Dec; 4 (6): 923-37
153. Feketi R. Vancomycin, teicoplanin, and the streptogramins: quinupristin and dalfopristin. In: Mandell GL, Bennett JEDR, editors. Principles and practice of infectious diseases. Philadelphia (PA): Churchill Livingstone, 2000: 382-92
154. Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005 Jan; 49 (1): 195-201
155. Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob Agents Chemother 2004 Aug; 48 (8): 3043-50
156. Chu S, Wilson DS, Deaton RL, et al. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 1993 Aug; 33 (8): 719-26

157. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. *J Antimicrob Chemother* 1990 Jan; 25 Suppl. A: 73-82
158. Craig WA. Does the dose matter? *Clin Infect Dis* 2001 Sep 15; 33 Suppl. 3: S233-237
159. Gattlinger R, Urbauer E, Traummüller F, et al. Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers. *Antimicrob Agents Chemother* 2004 Dec; 48 (12): 4650-3
160. Lodise TP, Preston S, Bhargava V, et al. Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. *Diagn Microbiol Infect Dis* 2005 May; 52 (1): 45-52
161. Conte Jr JE, Golden JA, Kipps J, et al. Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin. *Antimicrob Agents Chemother* 2004 Sep; 48 (9): 3508-15
162. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. *J Antimicrob Chemother* 2003 May; 51 Suppl. 2: ii17-25
163. Andes D, van Ogtrop ML, Peng J, et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). *Antimicrob Agents Chemother* 2002 Nov; 46 (11): 3484-9
164. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. *J Antimicrob Chemother* 2006 Aug; 58 (2): 256-65
165. Zhanel GG, Fontaine S, Adam H, et al. A Review of new fluoroquinolones: focus on their use in respiratory tract infections. *Treat Respir Med* 2006; 5 (6): 437-65
166. Arditì M, Mason Jr EO, Bradley JS, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. *Pediatrics* 1998 Nov; 102 (5): 1087-97
167. Flores-Cordero JM, Amaya-Villar R, Rincon-Ferrari MD, et al. Acute community-acquired bacterial meningitis in adults admitted to the intensive care unit: clinical manifestations, management and prognostic factors. *Intensive Care Med* 2003 Nov; 29 (11): 1967-73
168. Friedland IR, Klugman KP. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. *Lancet* 1992 Feb 15; 339 (8790): 405-8
169. Auburtin M, Wolff M, Charpentier J, et al. Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. *Crit Care Med* 2006 Nov; 34 (11): 2758-65
170. Andes DR, Craig WA. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. *Infect Dis Clin North Am* 1999 Sep; 13 (3): 595-618
171. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis* 2004 Nov 1; 39 (9): 1267-84
172. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant *Streptococcus pneumoniae*. *Clin Infect Dis* 2002 Sep 1; 35 (5): 556-64
173. Van Kerkhoven D, Peetermans WE, Verbist L, et al. Break-through pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. *J Antimicrob Chemother* 2003 Mar; 51 (3): 691-6
174. Daneman N, McGeer A, Green K, et al. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. *Clin Infect Dis* 2006 Aug 15; 43 (4): 432-8
175. Nuermberger E, Bishai WR. The clinical significance of macrolide-resistant *Streptococcus pneumoniae*: it's all relative. *Clin Infect Dis* 2004 Jan 1; 38 (1): 99-103
176. Peterson LR. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? *Clin Infect Dis* 2006 Jan 15; 42 (2): 224-33
177. Fuller JD, Low DE. A review of *Streptococcus pneumoniae* infection treatment failures associated with fluoroquinolone resistance. *Clin Infect Dis* 2005 Jul 1; 41 (1): 118-21
178. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. *Clin Infect Dis* 2003 Feb 15; 36 (4): 389-95
179. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. *Arch Intern Med* 2001 Aug 13; 161 (15): 1837-42
180. Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. *Arch Intern Med* 1999 Nov 22; 159 (21): 2562-72
181. Frei CR, Koeller JM, Burgess DS, et al. Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States Community-Acquired Pneumonia Project. *Pharmacotherapy* 2003 Sep; 23 (9): 1167-74
182. Harbarth S, Garbino J, Pugin J, et al. Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. *Eur J Clin Microbiol Infect Dis* 2005 Oct; 24 (10): 688-90
183. Mills GD, Oshley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. *BMJ* 2005 Feb 26; 330 (7489): 456
184. Shefet D, Robenshtock E, Paul M, et al. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. *Cochrane Database Syst Rev* 2005; (2): CD004418
185. Aspa J, Rajas O, Rodriguez DC, et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. *Eur Respir J* 2006 May; 27 (5): 1010-9
186. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. *Am J Respir Crit Care Med* 2004 Aug 15; 170 (4): 440-4
187. Garcia VE, Mensa J, Martinez JA, et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. *Eur J Clin Microbiol Infect Dis* 2005 Mar; 24 (3): 190-5
188. Arason VA, Sigurdsson JA, Erlendsdottir H, et al. The role of antimicrobial use in the epidemiology of resistant pneumococci: a 10-year follow up. *Microb Drug Resist* 2006; 12 (3): 169-76
189. Dagan R, Barkai G, Leibovitz E, et al. Will reduction of antibiotic use reduce antibiotic resistance?: the pneumococcus paradigm. *Pediatr Infect Dis J* 2006 Oct; 25 (10): 981-6
190. File Jr TM. Clinical implications and treatment of multidrug-resistant *Streptococcus pneumoniae* pneumonia. *Clin Microbiol Infect* 2006 May; 12 Suppl. 3: 31-41
191. Cunha BA. Antimicrobial therapy of multidrug-resistant *Streptococcus pneumoniae*, vancomycin-resistant enterococci, and methicillin-resistant *Staphylococcus aureus*. *Med Clin North Am* 2006 Nov; 90 (6): 1165-82
192. Varon E, Levy C, De La RF, et al. Impact of antimicrobial therapy on nasopharyngeal carriage of *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Branhamella catarrhalis* in children with respiratory tract infections. *Clin Infect Dis* 2000 Aug; 31 (2): 477-81
193. Ferrara AM. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance. *Infection* 2005 Jun; 33 (3): 106-14

194. Appelbaum PC, Jacobs MR. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. *Curr Opin Microbiol* 2005 Oct; 8 (5): 510-7
195. Van Bambeke F, Van Laethem Y, Courvalin P, et al. Glycopeptide antibiotics: from conventional molecules to new derivatives. *Drugs* 2004; 64 (9): 913-36
196. Douthwaite S. Structure-activity relationships of ketolides vs. macrolides. *Clin Microbiol Infect* 2001; 7 Suppl. 3: 11-7
197. Van Bambeke F, Glupczynski Y, Plesiat P, et al. Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. *J Antimicrob Chemother* 2003 May; 51 (5): 1055-65
198. Zhanel GG, Homenuik K, Nichol K, et al. The glycyclcyclines: a comparative review with the tetracyclines. *Drugs* 2004; 64 (1): 63-88
199. Pletz MW, Shergill AP, McGeeL, et al. Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of *Streptococcus pneumoniae* in the United States. *Antimicrob Agents Chemother* 2006 Apr; 50 (4): 1561-3
200. Schurek KN, Adam HJ, Siemens CG, et al. Are fluoroquinolone-susceptible isolates of *Streptococcus pneumoniae* really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003. *J Antimicrob Chemother* 2005 Oct; 56 (4): 769-72
201. Livermore DM. Can beta-lactams be re-engineered to beat MRSA? *Clin Microbiol Infect* 2006 Apr; 12 Suppl. 2: 11-6
202. Azoulay-Dupuis E, Bedos JP, Mohler J, et al. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. *Antimicrob Agents Chemother* 2004 Apr; 48 (4): 1105-11
203. Adis R&D profile. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788. *Drugs R D* 2006; 7(5): 305-11
204. Wilcox MH. Efficacy of linezolid versus comparator therapies in Gram-positive infections. *J Antimicrob Chemother* 2003 May; 51 Suppl. 2: ii27-35
205. San Pedro GS, Cammarata SK, Oliphant TH, et al. Linezolid versus ceftriaxone/cefepodoxime in patients hospitalized for the treatment of *Streptococcus pneumoniae* pneumonia. *Scand J Infect Dis* 2002; 34 (10): 720-8
206. Leclercq R. Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin. *J Antimicrob Chemother* 2001 Sep; 48 Suppl. T1: 9-23
207. Doern GV. Macrolide and ketolide resistance with *Streptococcus pneumoniae*. *Med Clin North Am* 2006 Nov; 90 (6): 1109-24
208. Wolter N, Smith AM, Low DE, et al. High-level telithromycin resistance in a clinical isolate of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2007 Mar; 51 (3): 1092-5
209. Hirakata Y, Mizuta Y, Wada A, et al. The first telithromycin-resistant *Streptococcus pneumoniae* isolate in Japan associated with erm(B) and mutations in 23S rRNA and riboprotein L4. *Jpn J Infect Dis* 2007 Feb; 60 (1): 48-50
210. Al Lahham A, Appelbaum PC, van der LM, et al. Telithromycin-nonsusceptible clinical isolates of *Streptococcus pneumoniae* from Europe. *Antimicrob Agents Chemother* 2006 Nov; 50 (11): 3897-900
211. Paratek Pharmaceuticals. Technology platforms: the tetracycline program [online]. Available from URL: http://www.paratekpharm.com/pt_tet_inhib.html [Accessed 2007 Mar 5]
212. Owens Jr RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. *Clin Infect Dis* 2005 Jul 15; 41 Suppl. 2: S144-157
213. Food and Drug Administration. Raxar (grepafloxacin) [online]. Available from URL: <http://www.fda.gov/medwatch/safety/1999/safety99.htm#raxar> [Accessed 2007 Mar 6]
214. Gurwitz JH. Serious adverse drug effects: seeing the trees through the forest. *N Engl J Med* 2006 Mar 30; 354 (13): 1413-5
215. Food and Drug Administration. Tequin (gatifloxacin) [online]. Available from URL: <http://www.fda.gov/medwatch/safety/2006/safety06.htm#Tequin> [Accessed 2007 Mar 6]
216. Schmid RE. Drug company taking tequin off market [online]. Available from URL: <http://www.sfgate.com/cgi-bin/article.cgi?file=/news/archive/2006/05/01/national/w120748D88.DTL&type=health> [Accessed 2007 Mar 6]
217. Galan MV, Potts JA, Silverman AL, et al. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center. *J Clin Gastroenterol* 2005 Jan; 39 (1): 64-7
218. Food and Drug Administration. Trovan (travofloxacin) [online]. Available from URL: <http://www.fda.gov/medwatch/safety/1999/safety99.htm#trovan2> [Accessed 2007 Mar 6]
219. Mera R. Predicting the future *Streptococcus pneumoniae* resistance landscape. *Curr Opin Pharmacol* 2005 Oct; 5 (5): 459-64

Correspondence: Dr Françoise Van Bambeke, Unité de Pharmacologie Cellulaire et Moléculaire, Université Catholique de Louvain, UCL7370 avenue Mounier 73, Brussels, 1200, Belgium.
E-mail: vanbambeke@facm.ucl.ac.be